JP2008544972A - 2,4-Diamino-pyrimidine as an aurora inhibitor - Google Patents

Abstract

The present invention relates to compounds of general formula (1), wherein R ^{1 to} R ³ are as mentioned in claim 1. Said compounds are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation. The present invention also relates to the use of said compound for the manufacture of a medicament having the aforementioned properties.
[Chemical 1]

Description

The present invention relates to novel 2,4-diamino-pyrimidines of general formula (1), their isomers, processes for the preparation of these pyrimidines and their use as pharmaceutical compositions.

(Wherein R ^{1 to} R ³ have the meanings given in the claims and herein).

  Tumor cells are characterized by uncontrolled growth, avoiding regulation and control by the body completely or partially. This is due, on the one hand, to the loss of regulatory proteins such as Rb, p16, p21 and p53 and to the activation of cyclin-dependent kinases called so-called cell cycle promoters.

  Studies in model organisms such as Schizosaccharomyces pombe, Drosophila melanogaster or Xenopus and studies in human cells show that the transition from G2 to mitosis is CDK1 / cyclin B kinase. (Nurse, 1990). This kinase is also known as “mitogenic factor” (MPF), for example, nuclear lamina, kinesin-like motor proteins, condensins and nuclear capsule degradation such as Golgi Matrix Protein. It phosphorylates and regulates a number of proteins that play important roles in body separation, spindle apparatus structure, chromosome condensation and Golgi degradation (Nigg, 2001). For example, treatment of human tumor cells with inhibitors against CDK1 / cyclin B, such as butyrolactone, results in G2 / M phase arrest and subsequent apoptosis (Nishio, et al. 1996).

In addition to cyclin-dependent kinases, so-called polo-like serine / threonine kinases (PLK-1, PLK-2, PLK-3 and PLK-4) play an important role in the regulation of the eukaryotic cell cycle. In particular, PLK-1 has been shown to play a central role in mitotic regulation. PLK-1 is involved in centrosome maturation for activation of Cdc25C phosphatase and for activation of the late facilitating complex (Glover et al., 1998, Qian et al., 2001). Injection of PLK-1 antibody results in tumor cell arrest during mitosis, while in non-transformed cells it results in G2 arrest (Lane and Nigg, 1996).
Furthermore, arrest in G2 / M phase is also due to inhibition of specific motor proteins called kinesins such as Eg5 (Mayer et al., 1999) or microtubule stabilizers or microtubule destabilizers. (Eg, colchicine, taxol, etoposide, vinblastine, vincristine) (Schiff and Horwitz, 1980).

  The Aurora family of serine / threonine kinases regulates various processes of cell division. These include chromosome condensation, spindle dynamics, centromere-microtubule interactions, chromosome orientation, metaphasis plate alignment and cytokinesis (Meraldi et al., 2004; Carmena and Earnshaw, 2003; Andrews et al., 2003). Three members of the family, Aurora A, B and C, have been described in mammals. While the yeast contains only one aurora gene known as IPL1 (in S. cerevisiae) or ARK1 (in S. pombe), the Caenorhabditis elegans And in Drosophila melanogaster, A and B type Aurora kinases are also present. All Aurora proteins share a similar overall structure including a variable N-terminus, a well-conserved central kinase region and a short C-terminal portion. Despite their sequence similarity, the Aurora family of kinases exhibits distinct subcellular localization associated with specialized functions.

  Thus, Aurora A can be found both on the centrosome close to the pole and on the spindle microtubules, in the interphase of the centrosome and during mitosis. Thus, as confirmed by RNA interference experiments, aurora A is essential for initiating mitosis because centrosome maturation and centrosome separation cannot occur when Aurora A is lost. There are various activators for Aurora A such as TPX2, Ajuba or protein phosphatase inhibitor 2. TPX2 appears to be involved in the correct activation of Aurora A in the space on the spindle microtubules at the right time and near the time (Hirota et al., 2003; Bayliss et al., 2003; Eyers and Maller, 2004; Kufer et al., 2002; Satinover et al., 2004).

  Aurora B binds to the condensed chromosomes in the early prophase, is located on the centromere in the middle metaphase, and then rearranges in the central zone of the central spindle, and finally daughter cells during cytokinesis Concentrate on the so-called framing or centrosome, which is a narrowly defined region between These characteristic spatial changes during mitosis justify calling Aurora B a so-called “chromosome passenger” protein. At least three other “chromosome passenger” proteins are known which form a complex with Aurora B. They are INCENP (inner centromere protein) survivin and borealin (Andrews et al., 2003; Carmena and Earnshaw, 2003; Meraldi et al., 2004). The important point of contact between Aurora B and this complex is provided by the C-terminus of INCENP, the so-called “IN box”. The “IN box” is the most highly conserved area of INCENP. The “IN box” binds and activates Aurora B and is phosphorylated by this kinase (Adams et al., 2000; Bishop and Schumacher, 2002; Kaitna et al., 2000; Bolton et al., 2002; Honda et al., 2003).

Aurora C is the least characterized member of the Aurora family. Aurora C has the next highest expression level of Aurora B, but Aurora C also binds to INCENP and behaves as a “chromosome passenger” protein. For example, since cells depleted of the multinucleated phenotype Aurora B can be normalized by the expression of Aurora C, Aurora C may probably inherit some function from Aurora B (Sasai et al., 2004; Li et al. , 2004).
Aurora B phosphorylates histone H3 at serine 10 and serine 28. This phosphorylation occurs during and at the time of chromosome condensation, but the effect of this event is only relevant late in the cell cycle. This is confirmed by the fact that histone H3 is concentrated in the mitotic chromosome by phosphorylation of serine 10 on the heterochromatin near the centromere and concomitant triple methylation of lysine 9. Histone H3 modified in this way suppresses the binding of heterochromatin protein 1 (HP1) and allows access to centromeric kinetochore regions by the “chromosome passenger” protein complex (Hirota T. et al., Manuscript in Preparation).

  One function of Aurora B revealed by inhibition of Aurora B exists in the binding of various proteins on the centromere during metaphase (Ditchfield et al., 2003; Hauf et al., 2003 Murata-Hori and Wang, 2002; Vigneron et al., 2004). Aurora B is central to the signal pathway that detects and corrects centromeric attachment of microtelematic (which is defective because they originate from only one spindle pole). Take a role (Andrews et al., 2003; Carmena and Earnshaw, 2003; Meraldi et al., 2004). If the state of attachment is not corrected, an error occurs in chromosome segregation. Aurora B-mediated phosphorylation of the microtubule depolymerase MCAK is associated with this correction mechanism (Gorbsky, 2004).

Aurora B is also a protein important for the formation of replication forms such as, for example, MgcRacGAP, myosin II regulatory light chain, vimentin, desmin, GFAP (glial fibrillary acidic protein) and kinesins MKLP1 and MKLP2, and for cytokinesis Among them, MKLP2 is probably involved in achieving transmission from the centromere to the centrosome of the “chromosome passenger” protein complex (Gruneberg et al., 2004).
In view of the various functions of Aurora B in the cell cycle, it has been found that inhibiting Aurora B in tumor cells does not cause mitosis, but rather causes continuation of the cell cycle without cytokinesis Was surprising (Hauf et al., 2003). As a result of the accumulation of syntelic microtubule-centromere attachment and thereby defective chromosome segregation, a large amount of ploidy occurs, ultimately leading to apoptosis. Simultaneous inhibition of equivalent Aurora A cannot act on this phenotype (Keen and Taylor, 2004).
Initially there were mainly signs of oncogenic activity of Aurora A (eg, transformation of mouse fibroblasts after overexpression), whereas for Aurora B, the signs were only indirectly present. (Zhou et al., 1998; Bischoff et al., 1998; Katayama et al., 1999). This was changed by the discovery that overexpression of Aurora B in embryonic hamster cells and its use in xenograft experiments directly increased tumor incidence, size and invasiveness. Corresponding tumors showed chromosomal instability and increased histone H3 serine 10 phosphorylation (Ota et al., 2002). These results demonstrate the importance of Aurora B during tumor development.
Pyrimidines are commonly known as kinase inhibitors. Thus, for example, substituted pyrimidines with a non-aromatic group at the 4-position as an active ingredient having anticancer activity are described in international patent applications WO 02/096888 and WO 03/032997.

  The object of the present invention is to present novel active substances that can be used for the prevention and / or treatment of diseases characterized by excessive or abnormal cell proliferation.

(Detailed description of the invention)
Surprisingly, compounds of general formula (1) act as inhibitors of specific cell cycle kinases, wherein the groups R ¹ , R ² and R ³ are as defined herein below. Was found. Thus, the compounds of the present invention may be used, for example, for the treatment of diseases associated with specific cell cycle kinase pseudonym and diseases characterized by excessive or abnormal cell proliferation.
The present invention is a compound of the general formula (1), which may be a tautomeric form, a racemate form, an enantiomer form, a diastereomer form or a mixture thereof, It may be in the form of those acid addition salts that are acceptable.

(Where
R ¹ means a group selected from C _3-10 -cycloalkyl and 3- to 8-membered heterocycloalkyl, R ⁵ as a substituent, and one or more R ⁴ As a substituent group;
R ² is selected from C _1-6 -alkyl, C _3-10 -cycloalkyl, 3 to 8 membered heterocycloalkyl, C _6-15 -aryl and 5 to 12 membered heteroaryl. Meaning a group, optionally having one or more R ⁴ as substituents;
R ³ is hydrogen, halogen, —CN, —NO ₂ , C _1-4 -alkyl, C _1-4 -haloalkyl, C _3-10 -cycloalkyl, C _4-16 -cycloalkylalkyl and C _7-16. Means a group selected from among arylalkyl;
R ⁴ means a group selected from R ^a , R ^b and R ^a having one or more of the same or different R ^c and / or R ^b as substituents;
R ⁵ is —C (O) R ^c , —C (O) NR ^c R ^c , —S (O) ₂ R ^c , —N (R ^f ) S (O) ₂ R ^c , —N (R ^f ) Means a suitable group selected from among: C (O) R ^c , —N (R ^f ) C (O) OR ^c and —N (R ^f ) C (O) NR ^c R ^c ;
Each of R ^a is C _1-6 -alkyl, C _3-10 -cycloalkyl, C _4-16 -cycloalkylalkyl, C _6-10 -aryl, C _7-16 -arylalkyl, 2 to 6 members Heteroalkyl, 3 to 8 membered heterocycloalkyl, 4 to 14 membered heterocycloalkylalkyl, 5 to 12 membered heteroaryl and 6 to 18 membered heteroarylalkyl independently of each other Selected;
Each of R ^b is a suitable group: ═O, —OR ^c , C _1-3 -haloalkyloxy, —OCF ₃ , —S, —SR ^c , ═NR ^c , ═NOR ^c , —NR ^c R ^c , halogen, —CF ₃ , —CN, —NC, —OCN, —SCN, —NO ₂ , —S (O) R ^c , —S (O) ₂ R ^c , —S (O) ₂ OR ^c , ^{-S (O) NR c R c} , -S (O) 2 NR c R c, -OS (O) R c, -OS (O) 2 R c, -OS (O) 2 OR c, -OS ( O) ₂ NR ^c R ^c , —C (O) R ^c , —C (O) OR ^c , —C (O) NR ^c R ^c , —CN (R ^f ) NR ^c R ^c , —CN (OH) R ^c , —CN (OH) NR ^c R ^c , —OC (O) R ^c , —OC (O) OR ^c , —OC (O) NR ^c R ^c , —OCN (R ^f ) NR ^c R ^c , ^{-N (R f) C (O} ) R c, -N (R f) C (S) R c, -N (R f) S (O) 2 R c, -N (R f) C (O) OR ^c , —N (R ^f ) C (O) NR ^c R ^c , — [N (R ^f ) C (O)] ₂ R ^c , —N [C (O)] ₂ R ^c , -N [C (O)] ₂ OR ^c ,-[N (R ^f ) C (O)] ₂ OR ^c and -N (R ^f ) CN (R ^f ) NR ^c R ^c Selected;
Each R ^c is independently of the other hydrogen or C _1-6 -alkyl, C _3-10 -cycloalkyl, C _4-11 -cycloalkylalkyl, C _6-10 -aryl, C _7-16 -arylalkyl 2 to 6 membered heteroalkyl, 3 to 8 membered heterocycloalkyl, 4 to 14 membered heterocycloalkylalkyl, 5 to 12 membered heteroaryl and 6 to 18 membered heteroarylalkyl. A group selected from the above, and optionally having one or more of the same or different R ^d and / or R ^e as a substituent;
Each R ^d is independently of one another hydrogen or C _1-6 -alkyl, C _3-8 -cycloalkyl, C _4-11 -cycloalkylalkyl, C _6-10 -aryl, C _7-16 -arylalkyl 2 to 6 membered heteroalkyl, 3 to 8 membered heterocycloalkyl, 4 to 14 membered heterocycloalkylalkyl, 5 to 12 membered heteroaryl and 6 to 18 membered heteroarylalkyl. A group selected from the above, and optionally having one or more of R ^e and / or R ^f as substituents;
Each of R ^e is a suitable group: ═O, —OR ^f , C _1-3 -haloalkyloxy, —OCF ₃ , ═S, —SR ^f , ═NR ^f , ═NOR ^f , —NR ^f R ^f , halogen, -CF ₃ , -CN, -NC, -OCN, -SCN, -NO ₂ , -S (O) R ^f , -S (O) ₂ R ^f , -S (O) ₂ OR ^f , ^{-S (O) NR f R f} , -S (O) 2 NR f R f, -OS (O) R f, -OS (O) 2 R f, -OS (O) 2 OR f, -OS ( O) ₂ NR ^f R ^f , —C (O) R ^f , —C (O) OR ^f , —C (O) NR ^f R ^f , —CN (R ^g ) NR ^f R ^f , —CN (OH) R ^f , —C (NOH) NR ^f R ^f , —OC (O) R ^f , —OC (O) OR ^f , —OC (O) NR ^f R ^f , —OCN (R ^g ) NR ^f R ^f , ^{-N (R g) C (O} ) R f, -N (R g) C (S) R f, -N (R g) S (O) 2 R f, -N (R d) C (O) OR ^f , —N (R ^g ) C (O) NR ^f R ^f and —N (R ^g ) CN (R ^f ) NR ^f R ^f Selected independently;
Each R ^f is independently of one another hydrogen or C _1-6 -alkyl, C _3-8 -cycloalkyl, C _4-11 -cycloalkylalkyl, C _6-10 -aryl, C _7-16 -arylalkyl 2 to 6 membered heteroalkyl, 3 to 8 membered heterocycloalkyl, 4 to 14 membered heterocycloalkylalkyl, 5 to 12 membered heteroaryl and 6 to 18 membered heteroarylalkyl. A group selected from the above, and may have one or more of the same or different R ^g as a substituent;
Each R ^g is independently of the other hydrogen, C _1-6 -alkyl, C _3-8 -cycloalkyl, C _4-11 -cycloalkylalkyl, C _6-10 -aryl, C _7-16 -arylalkyl 2 to 6 membered heteroalkyl, 3 to 8 membered heterocycloalkyl, 4 to 14 membered heterocycloalkyl, 5 to 12 membered heteroaryl or 6 to 18 membered heteroarylalkyl . )

One aspect of the invention relates to compounds of general formula (1), wherein R ³ represents a group selected from halogen and C _1-4 -haloalkyl.
In another aspect the invention relates to compounds of general formula (1), wherein R ³ represents —CF ₃ .
In another aspect, the present invention provides a compound of the general formula ( ^{2) wherein} R ² represents C _6-10 -aryl or 5- to 12-membered heteroaryl optionally having one or more R ⁴ as a substituent. It relates to the compound of 1).
In another aspect, the present invention relates to compounds of general formula (1) meaning that R ² represents phenyl optionally having one or more R ⁴ as substituents.
In another aspect the invention relates to compounds of general formula (1A).

(Where
n is 0 or 1;
m is 1-5,
y is 0-6,
The remaining groups are as defined above. )

In another aspect the invention relates to compounds of general formula (1A), wherein R ³ represents a group selected from halogen and C _1-4 -haloalkyl.
In another aspect the invention relates to compounds of general formula (1A), wherein R ³ represents CF ₃ .
In another aspect, the present invention provides a compound of the general formula ( ^{2) wherein} R ² represents C _6-10 -aryl or 5- to 12-membered heteroaryl optionally having one or more R ⁴ as a substituent. Relates to the compound of 1A).
In another aspect the invention relates to compounds of the general formula (1A), meaning that R ² represents phenyl optionally having one or more R ⁴ as substituents.

In another aspect, the present invention relates to a compound of general formula (1) or (1A) or a pharmaceutically active salt thereof for use as a pharmaceutical composition.
In another aspect, the invention relates to compounds of general formula (1) or (1A) for preparing pharmaceutical compositions having antiproliferative activity, their pharmaceutically active salts.
In another aspect, the present invention includes one or more of the compounds of general formula (1) or (1A) or physiologically acceptable salts thereof as an active substance, optionally containing conventional excipients and / or Or it relates to a pharmaceutical which may contain a carrier.

In another aspect, the present invention provides a compound of general formula (1) or (1A) for preparing a pharmaceutical composition for the treatment and / or prevention of cancer, infectious diseases, inflammatory diseases and autoimmune diseases. Regarding use.
In another aspect, the present invention relates to a compound of the general formula (1) or (1A), its tautomeric form, its racemic form, its enantiomeric form, its diastereomeric form or mixtures thereof And may be in the form of a pharmaceutically acceptable acid addition salt thereof and at least one other cytostatic active substance different from formula (1) or (1A) or The present invention relates to a medicine containing a cytotoxic active substance.

(Definition)
As used herein, the following definitions shall apply unless otherwise indicated.
Alkyl substituent means in each case a saturated, unsaturated, straight-chain or branched aliphatic hydrocarbon group (alkyl group), which definition includes a saturated alkyl group and an unsaturated alkenyl group and Both alkynyl groups are included. An alkenyl substituent is in each case a linear or branched unsaturated alkyl group having at least one double bond. Alkynyl substituent means in each case a straight-chain or branched unsaturated alkyl group having at least one triple bond.

Heteroalkyl means a straight or branched aliphatic hydrocarbon chain containing 1 to 3 heteroatoms, each of the available carbon and heteroatoms in the heteroalkyl chain being independently of each other. Optionally substituted, and the heteroatoms are independently selected from the group consisting of O, N, P, PO, PO ₂ , S, SO and SO ₂ (eg, dimethylaminomethyl, dimethylaminoethyl , Dimethylaminopropyl, diethylaminomethyl, diethylaminoethyl, diethylaminopropyl, 2-diisopropylaminoethyl, bis-2-methoxyethylamino, [2- (dimethylamino-ethyl) -ethyl-amino] -methyl, 3- [2- (Dimethylamino-ethyl) -ethyl-amino] -propyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxy, ethoxy Propoxy, methoxymethyl, 2-methoxyethyl).

Haloalkyl refers to an alkyl group in which one or more hydrogen atoms are replaced by halogen atoms. Haloalkyl includes, for example, —CF ₃ , —CHF ₂ , —CH ₂ F, —CF ₂ CF ₃ , —CHFCF ₃ , —CH ₂ CF ₃ , —CF ₂ CH ₃ , —CHFCF ₃ , —CH ₂ CF _{2. CF 3, -CF 2 CH 2 CH} 3, -CF = CF 2, -CCl = CH 2, -CBr = CH 2, -CJ = CH 2, -C≡C-CF 3, -CHFCH 2 CH 3 and - Both saturated alkyl groups such as CHFCH ₂ CF ₃ and unsaturated alkenyl and alkynyl groups are included. Halogen refers to fluorine, chlorine, bromine and / or iodine.

  Cycloalkyl means a monocyclic or polycyclic ring, and the ring system may be a saturated ring, but may also be an unsaturated non-aromatic ring or a spiro compound, and also a double ring. May include, for example, cyclopropyl, cyclopropenyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptanyl, cycloheptenyl, norbornyl, norbornenyl, indanyl, adamantyl, spiroheptanyl and spiro [4.2] heptanyl Such a thing is mentioned.

Cycloalkylalkyl includes an acyclic alkyl group in which a hydrogen atom bonded to a carbon atom is replaced by a cycloalkyl group.
Aryl relates to monocyclic or bicyclic rings having 6 to 12 carbon atoms such as, for example, phenyl and naphthyl.
Arylalkyl includes an acyclic alkyl group in which a hydrogen atom bonded to a carbon atom is replaced with an aryl group.

  Heteroaryl may be the same or different instead of one or more carbon atoms, for example monocyclic or polycyclic containing one or more heteroatoms such as nitrogen, sulfur or oxygen atoms. Means a cyclic ring. Examples include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl and triazinyl. Examples of bicyclic heteroaryl groups include indolyl, isoindolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, cinnolinyl , Phthalazinyl, quinazolinyl and benzotriazinyl, indolizinyl, oxazolopyridinyl, imidazopyridinyl, naphthyridinyl, indolinyl, isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, iso Benzothienyl, benzoxazolyl, pyridopyridinyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, Nyl, benzodioxolyl, triazinyl, phenoxazinyl, phenothiazinyl, pteridinyl, benzothiazolyl, imidazopyridinyl, imidazothiazolyl, dihydrobenzoisoxazinyl, benzisoxazinyl, benzooxazinyl, dihydrobenzoisothiazinyl , Benzopyranyl, benzothiopyranyl, coumarinyl, isocoumarinyl, chromonyl, chromanonyl, pyridinyl-N-oxide, tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinyl, dihydroisoquinolinyl, dihydrocoumarinyl, dihydroisocoumarin Nyl, isoindolinyl, benzodioxanyl, benzoxazolinonyl, pyrrolyl-N-oxide, pyrimidinyl-N-oxide, pyridazinyl-N-oxide, pyrazinyl-N-oxide, quinolinyl-N- Xoxide, indolyl-N-oxide, indolinyl-N-oxide, isoquinolyl-N-oxide, quinazolinyl-N-oxide, quinoxalinyl-N-oxide, phthalazinyl-N-oxide, imidazolyl-N-oxide, isoxazolyl-N-oxide, Oxazolyl-N-oxide, thiazolyl-N-oxide, indolizinyl-N-oxide, indazolyl-N-oxide, benzothiazolyl-N-oxide, benzimidazolyl-N-oxide, pyrrolyl-N-oxide, oxadiazolyl-N-oxide, thiadiazolyl- Examples include N-oxide, triazolyl-N-oxide, tetrazolyl-N-oxide, benzothiopyranyl-S-oxide and benzothiopyranyl-S, S-dioxide.

Heteroarylalkyl includes an acyclic alkyl group in which a hydrogen atom bonded to a carbon atom is replaced with a heteroaryl group.
Heterocyclyl is a saturated or unsaturated non-aromatic monocyclic, dicyclic, containing 3 to 12 carbon atoms having a heteroatom such as nitrogen, oxygen or sulfur instead of one or more carbon atoms. It relates to cyclic or bridged polycyclic rings or spiro compounds. Examples of such heterocyclyl groups include tetrahydrofuranyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, indolinyl, isoindolinyl, morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl, homopiperidinyl -Oxide, thiomorpholinyl-S, S-dioxide, tetrahydropyranyl, tetrahydrothienyl, homothiomorpholinyl-S, S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridinyl , Dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl-S-oxide, tetrahydrothienyl-S, S-dio Sid, homothiomorpholinyl-S-oxide, 2-oxa-5-azabicyclo [2.2.1] heptane, 8-oxa-3-aza-bicyclo [3.2.1] octane, 3,8-diaza-bicyclo [ 3.2.1] octane, 2,5-diaza-bicyclo [2.2.1] heptane, 3,8-diaza-bicyclo [3.2.1] octane, 3,9-diaza-bicyclo [4.2.1] nonane and 2,8 6-diaza-bicyclo [3.2.2] nonane.
Heterocycloalkylalkyl refers to an acyclic alkyl group in which a hydrogen atom bonded to a carbon atom is replaced with a heterocycloalkyl group.

The following examples illustrate the invention without limiting the scope of the invention.
(General)
Unless otherwise stated, all reactions were carried out using commercially available equipment by methods conventionally used in chemical laboratories. The solvent used was purchased in analytical grade and used without further purification. All reagents were used directly in the synthesis without purification. Air and / or moisture sensitive starting materials were stored under argon and the corresponding reactions and operations using them were carried out under protective gas (nitrogen or argon).

(Chromatography)
For preparative medium pressure chromatography (MPLC, normal phase), silica gel from Millipore (name: Granula Silica Si-60A 35-70 μm) or C-18 RP-silica gel (RP-phase) from Macherey Nagel (name: Polygoprep 100-50 C18) was used.
Thin layer chromatography was performed on ready-made glass silica gel 60TLC plates from Merck.
For preparative high-pressure chromatography (HPLC), use a column from Westers (name: XTerra Prep. MS C18, 5 μM, 30 × 100 mm or XTerra Prep. MS C18, 5 μm, 50 × 100 mm OBD or Symmetry C18 5 μm, 19 × 100 mm) and analytical HPLC (reaction control) were performed on an Agilent column (name: Zorbax SB-C8, 5 μm, 21.2 × 50 mm).
For chiral high-pressure chromatography (HPLC), columns made by Daicel Chemical Industries, Ltd. were used (name: Chiralpak AD-H or Chiralpak AS or Chiracel OD-RH or Chiracel of various sizes and 5 μm material) OD-H or Chiracel OJ-H in various sizes and 5 μm material).

(Nuclear resonance spectroscopy)
Nuclear resonance spectra were obtained using deuterated dimethyl sulfoxide-d6 as a solvent. If other solvents are used, these are clearly described in the examples or in the process. Chemical shifts were specified with respect to standard tetramethylsilane (δ = 0.00 ppm). The measured values were obtained using an Avance 400 (400 MHz-NMR spectrometer) or Avance 500 (500 MHz-NMR spectrometer) manufactured by Bruker Biospin GmbH.

(HPLC-mass spectrometry / UV spectroscopy)
Retention times / MS-ESI ⁺ to characterize the examples were generated using an Agilent HPLC-MS instrument (high performance liquid chromatography with mass detector). The instrument consists of a diode array detector (Agilent G1315B) and a mass detector (1100 LS-MSD SL; G1946D; Agilent) chromatography device (column: XTerra MS C18, 2.5 μm, 2.1 x 30 mm, Waters or Synergi POLAR-RP 80A; 4 μm, Phenomenex). The apparatus was operated at a flow rate of 1.1 mL / min. For the separation process, the gradient was run within 3.1 minutes (first part of the gradient: 95% water and 5% acetonitrile; gradient end: 5% water and 95% acetonitrile; in each case 0.1% formic acid was added to the two solvents).

(Melting point)
Melting points were obtained using a Buchi model B-540 apparatus and were not corrected.

  If the preparation of the starting compounds is not described, they are commercially available or may be prepared in the same manner as the known compounds or processes described herein.

(Preparation of compounds of the invention)
The compounds of the invention may be prepared by the synthetic methods described herein below, wherein the substituents of the general formula have the meanings given above. These processes are intended to illustrate the invention without limiting the subject matter and scope of the claimed compounds to the content of these examples.

If desired, conversion of one or more functional groups is also possible after formation of the diaminopyrimidine.

If desired, conversion of one or more functional groups (FG) is also possible after formation of diaminopyrimidine. This is described in the relevant examples.

(Preparation of starting compound)
Unless otherwise noted, all starting materials were purchased from commercial suppliers and used directly in the synthesis. The materials described in the literature were prepared according to published synthetic methods.
A-1) 2,4-Dichloro-5-trifluoromethyl-pyrimidine

While excluding moisture, 48 g (267 mmol) of 5-trifluoromethyluracil was suspended in 210 mL of phosphorus oxychloride (POCl ₃ ). 47.7 g (320 mmol, 1.2 eq) of diethylaniline was slowly added dropwise to the suspension so that the temperature remained at 25-30 ° C. After the addition was complete, the mixture was stirred in a water bath for an additional 5-10 minutes and the mixture was heated at 80-90 ° C. for 5-6 hours with exclusion of moisture. Excess POCl ₃ was quenched by stirring in about 1200 g of sulfuric acid-containing ice water and the aqueous phase was immediately extracted 3 times with 500 mL of ether or t-butyl-methyl-ether each time. The mixed ether-containing extract was washed twice with 300 mL of sulfuric acid-containing ice water (about 0.1 M) and once with cold saline and immediately dried over sodium sulfate. The desiccant was removed with a filter and the solvent was removed in vacuo. The residue was distilled under reduced pressure through a short column (20 cm) (head temperature: 65 ° C. to 70 ° C.) to obtain 35.3 g of a colorless liquid which was poured out and stored under argon. DC: R _f = 0.83 (cHex: EE = 3: 1)
A-2) 2-chloro-4-methylsulfanyl-5-trifluoromethyl-pyrimidine and
A-3) 4-Chloro-2-methylsulfanyl-5-trifluoromethyl-pyrimidine

Dissolve 5 g (23 mmol) 2,4-dichloro-5-trifluoromethyl-pyrimidine in 40 mL THF, adjust the solution to −25 ° C., and add 1.8 g (25.3 mmol, 1.1 eq) sodium thiol. Methoxide was added. The mixture was stirred at −25 ° C. for 1 hour and then stirred overnight at room temperature without cooling. It was then diluted with dichloromethane and washed 3 times with 1N HCl. The organic phase was dried over magnesium sulfate and evaporated in vacuo. The crude product was purified by column chromatography (silica gel, cyclohexane / dichloromethane; 90% / 10% to 80% / 20% in about 20 minutes). 1.56 g (6.8 mmol, 30%) of product A-3 and 1.46 g (6.4 mmol, 28%) of product A-2 were isolated as a colorless oil. In addition, 0.24 g (4%) of 2,4-bis-methylsulfanyl-5-trifluoromethyl-pyrimidine was isolated as a colorless solid.
Product A-3 Product A-2
R _f (cHex: CH ₂ Cl ₂ = 1: 1) 0.48 0.40

Structural analysis was performed by chemical derivatization followed by NMR spectroscopy. In this regard, A-2 and A-3 are first separated separately, in each case in THF at 100 ° C., 5 × 10 ² kPa (5 bar), 1: 1 ratio of Pd / C and Pd (OH). Dehalogenated with ₂ . Thanks to the different symmetry properties of the product formed, it is possible to clearly identify the regioisomer.
4-Amino-N-methyl-N-phenyl-benzenesulfonamide (extract in Example 1 (educt))

  Dissolve 9.5 mL (85.7 mmol, 98%) of N-methylaniline in 100 mL of dichloromethane and dissolve at 0 ° C in 20 mL (85.7 mmol, 95%) of 4-nitrobenzoylsulfonyl chloride dissolved in 150 mL and dichloromethane. Was added dropwise and the mixture was stirred for an additional 1.5 hours. The organic layer was washed with a saturated aqueous sodium carbonate solution and dried over sodium sulfate. Finally, it was filtered through silica gel and once all volatile components were removed under reduced pressure, 24.6 g of crude N-methyl-4-nitro-N-phenyl-benzenesulfonamide was obtained.

14.6 g (49.9 mmol) of nitrosulfonic acid amide was dissolved in 100 mL of THF / MeOH 1/1. After addition of Pd / C (10%), the mixture was stirred for 16 hours at 50 ° C. under 5 × 10 ² kPa (5 bar) H ₂ . After adding molecular sieves to constrain water, Pd / C is further added and further stirred for 16 hours under hydrogenation conditions (5 × 10 ² kPa (5 bar) H ₂ , 60 ° C.) to give 13.1 g ( 48.9 mmol, 100%) of crude A-4a was obtained as a beige solid. The crude product was used for synthesis without any further purification.

  4-Amino-N-phenyl-benzenesulfonamide and 4-amino-N, N-dimethyl-benzenesulfonamide were prepared in the same way (educt in Examples 2 and 3). The method described has been a generally applicable process for preparing substituted or unsubstituted aminobenzene sulfonic acid amides from the corresponding nitrobenzene sulfonic acid chloride.

R ³ -substituted 2,4-dichloropyrimidine B-1 corresponding to the general procedure specified for the synthesis of compounds of type B-2 (A-1 as described commercially available or corresponding uracil Prepared by chlorination according to the examples described above, dissolved in THF (or dioxane, DMA, NMP, acetone) (about 2-5 mL / mmol) and 1-1.6 eq Hunig's base (or triethylamine) , Potassium carbonate or other suitable base) was added to adjust the temperature of the reaction mixture (−78 ° C. for highly reactive pyrimidines, rather RT or elevated temperature for non-reactive pyrimidines). Next, 0.75 to 1 eq of amine dissolved in the corresponding solvent (see above) is added and the reaction mixture is stirred at the corresponding temperature for the specified time or thawed for the specified time, depending on the reactivity of the pyrimidine used. Or heated. After the reaction was complete (reaction monitored by HPLC or DC), the reaction mixture was mixed with silica gel and all volatile components were removed under reduced pressure. Purification by column chromatography yielded the desired substituted product. Depending on the pyrimidine group R3, the two possible regioisomers were obtained in different proportions. They can usually be separated by chromatography.
B-2a) (±)-(1S ^* , 2R ^* )-2- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -cyclopentane-carboxamide

500 mg (2.3 mmol) A-1 and 636 mg (4.6 mmol, 2 eq) potassium carbonate were suspended in 11 mL acetone, cooled to -70 ° C, then cis- (±)-(1S .2R) -2-Amino-cyclopentanecarboxamide was added. The reaction was left to thaw overnight with stirring at RT and then stirred for an additional 24 hours at ambient temperature. Next, 40 mL of silica gel was added and all volatile components were removed under reduced pressure. The desired regioisomer was the first eluted product (silica gel, cHex / EE 40/60), but the two regioisomer products were separated by column chromatography. 218 mg (0.71 mmol, 31%) of B-2a and 297 mg (0.96 mmol, 42%) of the regioisomer product B-2′a were separated.
R _f (B-2a) = 0.51 (silica gel, EE), [R _f (B-2a ') = 0.34]
MS-ESI +: 309 (M + H) ⁺

The structure of the two regioisomers is purified by separation dehalogenation of the product under reducing conditions followed by 1H-NMR spectroscopy (as for A-2 and A-3). Categorized.

The compound of type B-2 in the following examples was synthesized in the same manner.

The basic procedure educt B-2 specified for the synthesis of compounds of type B-4 is dissolved in 1-butanol (or dioxane, DMA, NMP) (about 0.5-4 mL / mmol) to give dioxane. 0.1-1 eq of HCl in was added and 1 eq of aniline and the reaction mixture were refluxed. After the reaction was completed, the reaction mixture was mixed with silica gel and all volatile components were removed under reduced pressure. The mixture was then purified by column chromatography. In many cases, the product was precipitated from the reaction solution immediately after the reaction was completed, and could be directly filtered by suction and washed with 1-butanol.

(4-Amino-2-chloro-phenyl)-(4-methyl-piperazin-1-yl) -methanone (educt in Example 70)

1 mL (8.84 mmol, 1.3 eq) N-methylpiperazine was dissolved in 40 mL dichloromethane and this solution was mixed with 1.5 mL (8.84 mmol, 1.3 eq) Hunig's base. Then 1-5 g (6.82 mol, 1 eq) 4-nitro-2-chlorobenzoyl chloride dissolved in 10 mL dichloromethane was slowly added dropwise with cooling. After 2 hours, 9 mL of saturated aqueous sodium bicarbonate was slowly added with stirring, the organic phase was separated and the solvent was removed under reduced pressure. The product was purified by column chromatography (silica gel, DCM / MeOH / NH ₃ 9/1/01) to give 1.83 g (6.45 mmol, 95%) of nitrobenzoic acid amide. The latter was dissolved in 2 L of THF, 300 mg of Rainey nickel was added, and the mixture was stirred at room temperature for 16 hours at 3 × 10 ² kPa (3 bar) H ₂ pressure. After filtering the Raney nickel, the volatile constituents were removed under reduced pressure and 1.2 g (4.73 mmol, 73%) of (4-amino-2-chloro-phenyl)-(4-methyl-piperazine-1- Il) -methanone.
R _f = 0.38 (silica gel, DCM: MeOH: NH ₃ = 9: 1: 0.1)
MS-ESI ⁺ : 254 (M + H) ⁺

The method is equally suitable for the synthesis of substituted and unsubstituted aminobenzoic acid amides, for example as used in the synthesis of Examples 71-75. These examples were prepared as in Example 70. In the synthesis of Examples 106, 107 and 144, m-aminobenzoic acid amide prepared by the same method was used.
cis- (±) -2-Amino-cyclopentanecarboxylic acid-isopropylamide

55 mg (0.43 mmol) cis- (±) -2-amino-cyclopentanecarboxylic acid was suspended in 900 μL (25 eq) isopropylamine, 205 mg (0.064 mmol, 1.5 eq) TBTU and 550 μL Of DMF was added to this suspension. This was stirred for 16 hours and the reaction mixture was transferred into DCM: MeOH: NH ₃ = 9: 1: 0.1 and mixed with 7 mL of silica gel. After removing all volatile components under reduced pressure, the mixture was chromatographed (silica gel, DCM: MeOH: NH ₃ = 9: 1: 0.1). 63 mg (0.37 mmol, 86%) of a colorless solid was obtained.
R _f = 0.33 (silica gel, DCM: MeOH: NH ₃ = 85: 15: 1.5)
B-2g) (±)-(1S ^* , 2R ^* )-2- (2-chloro-5-trifluoromethyl-pyrimidin-4-ylamino) -cyclopentane-carboxylic acid isopropylamide

2 g (9.2 mmol) A-1 and 1.8 mL (11.2 mmol, 1.2 eq) Hunig's base are dissolved in 60 mL THF, the mixture is cooled to −78 ° C. and then in 60 mL THF. Cis- (±) -2-amino-cyclopentanecarboxylic acid isopropylamide dissolved in was slowly added dropwise at -78 ° C. The reaction was thawed at room temperature overnight with stirring. Next, 40 mL of silica gel was added and all volatile components were removed under reduced pressure. The two regioisomer products were separated by column chromatography, with the preferred regioisomer being the first eluting product (silica gel, cHex / EE 85/15 to 80/20 for 30 min). 590 mg (1.68 mmol, 24%) of B-2g and 690 mg (1.97 mmol, 28%) of the regioisomer product B-2g ′ were isolated.
R _f (B-2g) = 0.21 (silica gel, cHex: EE = 3: 1), [R _f (B-2g ′) = 0.10]
MS-ESI +: 351 (M + H) ⁺
UV _max = 246 nm
3-Fluoro-4- (4-methyl- [1.4] diazepan-1-yl) -phenylamine

Dissolve 2 g (12.6 mmol) of 3,4-difluoronitrobenzene in 1.6 mL of ethanol, add 2.4 mL (15.1 mmol, 1.2 eq) of Hunig's base, and then add 1.44 g (12.6 mmol, 1 eq) of hexahydro -1-Methyl-1H-1.4-diazepine was added dropwise with ice cooling. After stirring for about 12 hours at room temperature, the reaction was complete. Next, methanol and 50 mL of silica gel were added, the volatile components were removed under reduced pressure, and the mixture was purified by column chromatography (DCM / MeOH for 35 minutes, 97/3 to 85/15). 3 g (11.9 mmol, 94%) of the nitro compound was obtained.
R _f = 0.39 (silica gel, DCM: MeOH: NH ₃ = 9: 1: 0.1)
MS-ESI ⁺ : 253 (M + H) ⁺

The nitro compound was dissolved in 600 mL of THF and mixed with about 300 mg of Rainey nickel. The mixture was hydrogenated at 3 × 10 ² kPa (3 bar) H ₂ pressure for 3 hours. Raney nickel was filtered and the solution was depressurized to remove all volatile components. 2.15 g (9.6 mmol, 81%) of 3-fluoro-4- (4-methyl- [1.4] diazepan-1-yl) -phenylamine was obtained.
R _f = 0.48 (silica gel, DCM: MeOH: NH ₃ 4: 1: 0.1)
MS-ESI +: 224 (M + H) ⁺
The aniline used as the educt in Examples 142-143 was prepared in the same manner.
Benzyl 4-amino-benzoate

11.01 g of 4-nitrobenzoic acid was suspended in 500 mL of acetonitrile and then mixed with 15.03 g (108.7 mmol, 1.2 eq) of potassium carbonate. 15.40 g (171.0 mmol, 1 eq) benzylbromide ais was added dropwise with stirring and then the reaction mixture was heated to 60 ° C. with stirring for 5 hours. This was mixed with 750 mL of distilled water, extracted with 4 × 250 mL of EE, the organic phase was mixed and dried over sodium sulfate. After removing all volatile components under reduced pressure, the crude product was suspended twice in toluene in succession and removed under reduced pressure to remove all volatile components (removal of excess benzyl bromide). . 20.60 g (80.1 mmol) of benzyl 4-nitro-benzoate was obtained as a colorless solid and used in the next step without further purification. 20.6 g of benzyl 4-nitro-benzoate was dissolved in 350 mL of dioxane and the solution was mixed with 6.9 g (49.9 mmol, 0.61 eq) of Raney nickel. The mixture was hydrogenated with stirring at a H ₂ pressure of 5 × 10 ² kPa (5 bar) for 16 hours. The catalyst was filtered and reduced in pressure to remove all volatile components. 17.0 g (74.8 mmol, 93%) of benzyl 4-aminobenzoate were obtained in the form of a colorless solid.
C-1a) Benzyl 4- (4-chloro-5-trifluoromethyl-pyrimidin-2-ylamino) -benzoate

Dissolve 10 g (44 mmol) of benzyl 4-aminobenzoate in 200 mL of DMA, add 8 mL of Hunig's base (0.79 eq), and dissolve 10.4 g (48.21 mmol) of 2, dissolved in 50 mL of DMA. 4-Dichloro-5-trifluoromethylpyrimidine was added dropwise to the clear solution at room temperature. The reaction solution was stirred at 60 ° C. overnight, then mixed with 300 mL of dichloromethane and extracted with distilled water (3 × 300 mL). The organic phase was dried over sodium sulfate and the solvent was removed under reduced pressure. The crude product was mixed with 100 mL of MeOH, digested and allowed to stand for 2 hours. The mixture was then stirred for 10 minutes and the precipitate was filtered and washed with methanol (the methanolic filtrate contained unwanted nucleophilic substituted regioisomers). Finally, the crude product was suspended once more in methanol, filtered, washed with a small amount of methanol and dried at 60 ° C. in a vacuum dryer. 8.5 g (20.7 mmol, 43%) of C-1a was obtained in the form of a pale yellow solid.
R _f = 0.71 (silica gel, cHex: EE 1: 2)
MS-RSI ⁺ : 408 (M + H) ⁺
C-2a) [4- (4-Chloro-5-trifluoromethyl-pyrimidin-2-ylamino) -phenyl]-(4-methyl-piperazin-1-yl) -methanone

2.74 g (6.71 mmol) C-1a is dissolved in 120 mL dioxane, 300 mg palladium hydroxide (20% w / w Pd, 2.14 mmol, 0.32 eq) is added and the mixture is 3 × 10 ^2. Stir for 16 hours at room temperature with H ₂ pressure of kPa (3 bar). The reaction mixture was filtered through Celite, the solvent was removed under reduced pressure and 1.87 g (5.89 mmol, 88%) of 4- (4-chloro-5-trifluoromethyl-pyrimidin-2-ylamino)- Benzoic acid was obtained as a colorless solid and used without further purification. 1.1 g (3.46 mmol) benzoic acid was mixed with 20 mL toluene and 301 μL (4.16 mmol, 1.2 eq) thionyl chloride and refluxed for 1.5 hours. All volatile components were removed under reduced pressure and the crude benzoic acid chloride was reacted more directly.

The 536 mg (1.6 mmol) was dissolved in 4 mL THF and mixed with 410 μL (1.5 eq) Hunig's base. After adding 179 μL (1 eq) N-methylpiperazine, the solution was stirred at room temperature for 16 hours. The reaction mixture was poured into about 40 mL of distilled water, stirred for 30 minutes, and the aqueous phase was extracted 3 times with 50 mL of ethyl acetate. The organic phase was dried over magnesium sulfate and then reduced in pressure to filter and remove volatile components to obtain 645 mg (1.5 mmol, 94%) of C-2a as a solid.
R _f = 0.69 (silica gel, CH ₂ Cl ₂ : MeOH: NH ₃ 5: 1: 0.1)
MS-ESI +: 400 (M + H) ⁺
C-2b) 4- (4-Chloro-5-trifluoromethyl-pyrimidin-2-ylamino) -N-methyl-N- (1-methyl-piperidin-4-yl) -benzamide

R _f = 0.30 (silica gel, CH ₂ Cl ₂ : MeOH: NH ₃ 5: 1: 0.1)
MS-ESI +: 428 (M + H) ⁺
C-2b was prepared in the same manner as C-2a using methyl- (1-methyl-piperidin-4-yl) -amine.
Benzyl (±)-((1S ^* , 2R ^* )-2-amino-cyclohexyl) -carbamate

2 mL (16.2 mmol) cis-1,2-diaminocyclohexane and 2.42 g (19.4 mmol, 1.2 eq) 9-borabicyclo [3.3.1] nonane (9-BBN) in 8 mL THF / NMP 1/1. Dissolved and stirred at room temperature for 45 minutes. 2.4 mL (16.2 mmol, 1 eq) of benzyl chloroformate (Cbz-chloride) was added to the slightly cloudy solution. After about 1 hour, the reaction mixture was mixed with distilled water and stirred for several minutes. The aqueous solution was then mixed with ethyl acetate and the aqueous phase was washed 3 times with about 50 mL of ethyl acetate. The aqueous phase was made alkaline with NaHCO ₃ (pH 8), mixed with dichloromethane, extracted three times with 10 mL of dichloromethane, the mixed organic phase was dried over magnesium sulfate, and the solvent was removed under reduced pressure. 2.29 g (9.22 mmol, 57%) of benzyl (±)-((1S ^* , 2R ^* )-2-amino-cyclohexyl) -carbamate was obtained as a colorless oily liquid.
R _f = 0.45 (silica gel, CH ₂ Cl ₂ : MeOH: NH ₃ 9: 1: 0.1)
MS-ESI ⁺ : 249 (M + H) ⁺
C-3a) benzyl (±)-((1S ^* , 2R ^* )-2- {2- [4- (4-methyl-piperazine-1-carbonyl) -phenylamino] -5-trifluoromethyl-pyrimidine- 4-ylamino} -cyclohexyl) -carbamate

800 mg (2 mmol) C-2a dissolved in 1 mL NMP with 569 mg (2.4 mmol, 1.2 eq) benzyl (±)-((1S ^* , 2R ^* )-2-amino-cyclohexyl) -carbamate Then, 521 μL (3 mmol, 1.5 eq) of Hunig's base was added. After 48 hours at 70 ° C., the reaction was terminated. After removing the solvent under reduced pressure, the crude product was purified by column chromatography (DCM / MeOH / NH ₃ 19/1 / 0.1 to 9/1 / 0.1) and 826 mg (1.35 mmol, 68% ) In the form of a colorless resin.
MS-ESI ⁺ : 612 (M + H) ⁺
C-3b) (±)-{4- [4-((1R ^* , 2S ^* )-2-amino-cyclohexylamino) -5-trifluoromethyl-pyrimidin-2-ylamino] -phenyl}-(4- Methyl-piperazin-1-yl) -methanone

112 mg (0.18 mmol) of C-3a was dissolved in DMF (10 mL) and mixed with distilled water (1 mL). Next, another 9 mL of DMF was added and the solution was transferred to a hydration apparatus and mixed with Pd / C (200 mg, 5% Pd). The reaction solution was stirred at 4 × 10 ² kPa (4 bar) H ₂ pressure for 12 hours. The reaction mixture was transferred into dichloromethane, mixed with 10 mL of RP-gel and all volatile components were removed under reduced pressure. Purification was carried out by column chromatography (RP-phase, acetonitrile / water 5/95 to 95/5 in 20 minutes). The product fractions were mixed and then lyophilized to give 27 mg (0.06 mmol, 30%) of the preferred product as a colorless solid.
MS-ESI ⁺ : 478 (M + H) ⁺
C-3c) (±)-(1S ^* , 2R ^* )-2- {2- [4- (4-Methyl-piperazine-1-carbonyl) -phenylamino] -5-trifluoromethyl-pyrimidine-4- Ilamino} -cycloheptanecarboxylic acid

440 mg (1.1 mmol) C-2a was dissolved in 500 μL NMP and mixed with 565 μL Hunig base (3.3 mmol, 3 eq) and 256 mg cis-2-aminocycloheptanecarboxylic acid (racemic). The reaction mixture was placed in an oil bath maintained at 100 ° C. and heated to this temperature with stirring for 8 hours. After completion of the reaction, the reaction mixture was taken up in methanol and mixed with 20 mL RP-gel and all volatile components were removed under reduced pressure. Purification was performed by reverse phase (eluent: acetonitrile / water 15/85 to 35/65 for 15 minutes). After mixing the product fractions and lyophilizing, 160 mg (0.31 mmol, 28%) of the preferred product was obtained as a colorless solid.
MS-ESI ⁺ : 521 (M + H) ⁺
C-3d) (±)-(1S ^* , 2R ^* )-2- {2- [4- (4-Methyl-piperazine-1-carbonyl) -phenylamino] -5-trifluoromethyl-pyrimidine-4- Ilamino} -cyclopentanecarboxylic acid

563 mg (1.13 mmol) of C-2a was dissolved in 5 mL of 1-butanol, and 163 mg of cis-2-amino-1-cyclopentanecarboxylic acid (racemic) was added thereto. After adding 540 μL of Hunig base, the mixture was heated to 110 ° C. for about 60 minutes (microwave, CEM, 100 W). The reaction mixture was evaporated under reduced pressure, stirred with about 100 mL of water and extracted 3 times with 50 mL of ethyl acetate. The mixed organic phase was dried over magnesium sulfate and the solvent was removed under reduced pressure. 530 mg (1.08 mmol, 96%) of C-3d was obtained.
MS-ESI ⁺ : 493 (M + H) ⁺
C-3e was prepared in the same way using DMA as solvent and C-2b as starting material.

MS-ESI ⁺ : 521 (M + H) ⁺
C-3f) (1S, 3R) -3- (2- {4- [Methyl- (1-methyl-piperidin-4-yl) -carbamoyl] -phenylamino} -5-trifluoromethyl-pyrimidine-4- Ylamino) -cyclopentanecarboxylic acid

200 mg of C-2b was dissolved in 750 μL of DMA and 160 μL (0.93 mmol, 2 eq) Hunig's base was added. Then 72 mg (0.56 mmol, 1.2 eq) of (1S, 3R) -3-aminocyclopentane-carboxylic acid was added and the reaction mixture was heated to 120 ° C. for 40 minutes. The reaction mixture was mixed with RP-gel, volatile components were removed under reduced pressure, and the product was isolated by purification by column chromatography through the RP-phase (85% water (+ 0.2% HCOOH) and 15% acetonitrile (+ 0.2% HCOOH) to 76% water and 24% acetonitrile). Corresponding product fractions were mixed and the solvent was removed by lyophilization to give 150 mg (0.29 mmol, 62%) of C-3f as a colorless film.
(±) -trans-2-aminocyclopentanecarboxamide

The compound was prepared according to the literature (Csomos et al., 2002).
D-2a) Benzyl 4- [4-((1R.2S) -2-carboxy-cyclopentylamino) -5-trifluoromethyl-pyrimidin-2-ylamino] -benzoate

2.05 g (5 mmol) of C-1a and 1 g of (1S.2R)-(+)-2-amino-1-cyclopentanecarboxylic acid hydrochloride (6 mmol, 1.2 eq) were placed in 18 mL of ethanol. 7.3 mL (42.5 mmol, 3.4 eq) Hunig's base was added and the mixture was stirred at 70 ° C. for 4 hours. The reaction mixture is stirred in 275 mL of water, filtered to remove undissolved material, the filtrate is adjusted to pH 2 with saturated aqueous KHSO ₄ solution, stirred for 5 minutes, and the precipitate formed is aspirated. Filtered. The crude product was pruned with water, dried in vacuo and 2.37 g (4.74 mmol, 94%) of D-2a was obtained in the form of a light beige solid.
MS-ESI ⁺ : 501 (M + H) ⁺
Same synthesis with (1R, 2S)-(-)-2-amino-1-cyclopentanecarboxylic acid derivative or (1R ^* , 2S ^* )-(±) -2-amino-1-cyclopentanecarboxylic acid derivative Went so. The corresponding products are D-2b (chiral, enantiomer of D-2a) and D-2c (racemic).
Preparation of (1S, 2R) -2-aminocyclopentanecarboxylic acid hydrochloride

22.64 mL (0.26 mmol, 0.95 eq) of CSI was added dropwise to 23 mL (0.273 mol, 1 eq) of cyclopentane under argon at −75 ° C. During the addition, the reaction temperature was always kept below -65 ° C. The reaction was allowed to warm to room temperature over 2 hours and further stirred overnight. The reducing working up was performed by adding the reactants dropwise to a 600 mL ice / water solution containing 60 g sodium sulfite and 180 g NaHCO ₃ . The aqueous phase was extracted four times with 200 mL of dichloromethane, the organic phases were combined, dried over magnesium sulfate and reduced in pressure to remove all volatile components. 25.75 g (85%) of slightly yellowish crystals were obtained.
Dissolve these in 400 mL diisopropyl ether, add 1.6 mL water and 20 g resin-bound lipolase (lipase acrylic resin from Candida antartica, Sigma-Aldrich) and add the mixture. Shake at 60 ° C. for 11 days. The reaction suspension was filtered through Celite, washed with diisopropyl ether and the filtrate was evaporated to dryness. The resulting yellowish oil was taken up in 200 mL of dichloromethane and washed with about 150 mL of saturated NaHCO ₃ solution. The aqueous phase was extracted three times with dichloromethane, the organic phases were combined and dried over magnesium sulfate. After removing all volatile constituents under reduced pressure, 8.93 g of chiral lactam was obtained in the form of a yellowish oil.
The latter product was dissolved in 10 mL of water and 10 mL of 37% HCl (aq) was added with cooling and stirring in an ice bath. After stirring at 0 ° C. for 10 minutes, the reaction solution was allowed to stand overnight at room temperature. The precipitated crystals were filtered, washed with a small amount of acetonitrile and dried under high vacuum. The mother liquor was evaporated to near dryness and the precipitated crystals were filtered, washed with acetonitrile and further dried under high pressure. 11.74 g (70.9 mmol, 31% based on racemic lactam) of (1S, 2R) -2-aminocyclopentanecarboxylic acid hydrochloride in the form of colorless crystals (the kinetic resolution of the enantiomer acid) And was contained in the precipitate separated by filtration through Celite). The order of the synthesis is described in the literature (Forro and Fueloep, 2003).
D-3a) Benzyl 4- [4-((1R, 2S) -2-isopropylcarbamoyl-cyclopentylamino) -5-trifluoromethyl-pyrimidin-2-ylamino] -benzoate

2.59 g (4.9 mmol) D-2a, 2.21 g (6.9 mmol, 1.4 eq) TBTU and 4.21 mL (24.6 mmol, 5 eq) Hunig's base were dissolved in 75 mL DMF and stirred at room temperature for 20 minutes. . Then 0.63 mL (7.38 mmol, 1.5 eq) isopropylamine was added and the mixture was stirred at room temperature overnight. It was suction filtered through basic aluminum oxide, washed with DMF, the mother liquor was stirred in 400 mL of water, stirred for a further 30 minutes and the precipitate was filtered off with suction. The crude product was washed with water and dried under reduced pressure. For purification, it was stirred with 50 mL of acetonitrile at 5 ° C. for 30 minutes, filtered with suction, washed with some cold acetonitrile and the residue was dried under reduced pressure. 2.13 g (3.9 mmol, 80%) of D-3a was obtained in the form of a light beige solid.
R _f = 0.53 (silica gel, cHx: EE 1: 1)
MS-ESI ⁺ : 542 (M + H) ⁺
D-4a) 4- [4-((1R, 2S) -2-isopropylcarbamoyl-cyclopentylamino) -5-trifluoromethyl-pyrimidin-2-ylamino] -benzoic acid

2.13 g (3.9 mmol) of D-3a was dissolved in 150 mL of THF and 250 mg of palladium hydroxide / C-catalyst (20 wt.% Pd on charcoal) was added. The mixture was hydrogenated with stirring at room temperature at 6 × 10 ² kPa (6 bar) H ₂ pressure for 16 hours. Then 30 mL of methanol was added and the catalyst was filtered through diatomaceous earth, washed with methanol and the filtrate was evaporated. The residue was boiled with 45 mL of ethanol, cooled slowly to 5 ° C., stirred for an additional hour, then filtered off with suction and washed with cold ethanol. 2.46 g (3.2 mmol, 82%) of D-4a acid was obtained.
R _f = 0.46 (silica gel, CH ₂ Cl ₂ : MeOH: AcOH 5: 1: 0.1)
MS-ESI ⁺ : 452 (M + H) ⁺
Enantiomeric and racemic compounds were synthesized in the same way.

D-5c) t-Butyl (±)-{4- [4-((1R ^* , 2S ^* ) -2-Isopropylcarbamoyl-cyclopentylamino) -5-trifluoromethyl-pyrimidin-2-ylamino] -phenyl} -carbamate

450 mg (1 mmol) D-4c was dissolved in 1.8 mL dry toluene and 222 μL (1.3 mmol, 1.3 eq) Hunig's base and 940 μL t-butanol were added sequentially. Then 258 μL of diphenylphosphoryl azide was added and the mixture was heated to 80 ° C. for 16 hours. The reaction mixture was mixed with 20 mL ethyl acetate, washed twice with 20 mL 0.5 M NaOH solution and the aqueous phase was counter-washed twice with 20 mL ethyl acetate. The mixed organic phase was washed with a saturated aqueous sodium chloride solution, insoluble components were filtered, the filtrate was dried over magnesium chloride, and the solvent was removed under reduced pressure. 461 mg (0.88 mmol, 89%) of D-5c was obtained in the form of a yellowish solid.
MS-ESI ⁺ : 523 (M + H) ⁺
D-6c) (±)-(1S ^* , 2R ^* )-2- [2- (4-amino-phenylamino) -5-trifluoromethyl-pyrimidin-4-ylamino] -cyclopentanecarboxylic acid-isopropylamide

461 mg (0.88 mmol) D-5c was dissolved in 5 mL dichloromethane, 2 mL trifluoroacetic acid was added and the mixture was stirred at room temperature for 1 hour. The reaction mixture was stirred in 50 mL of water and the aqueous phase was washed with 50 mL of ethyl acetate. The organic phase was further extracted twice with 30 mL of 10% hydrochloric acid, the aqueous phase was mixed, adjusted to pH 10 with 10% sodium hydroxide solution, and extracted three times with 50 mL of ethyl acetate. The mixed organic phase was dried over magnesium sulfate and volatile components were removed under reduced pressure to give 243 mg (0.58 mmol, 65%) of D-6c as a colorless solid.
R _f = 0.08 (silica gel, cHex: EE 1: 1)
MS-ESI ⁺ : 423 (M + H) ⁺
E-1) 2-Methylsulfanyl-1H-pyrimidin-4-one

20 g (153 mmol) of 2-thiouracil was suspended in 250 mL of methanol and then 837 g (152.9 mmol, 1 eq) of sodium methoxide was added. The solution was stirred at room temperature for 5 minutes and then 12.4 mL (198.8 mmol, 1.3 eq) of methyl iodide was added dropwise. The reaction mixture was stirred overnight and then poured into water and extracted three times with about 150 mL of chloroform. The mixed organic phase was dried over magnesium sulfate and the solvent was removed under reduced pressure to give 16 g (121.5 mmol, 74%) of E-1 as a colorless solid.
E-2) 4- (6-Oxo-1,6-dihydro-pyrimidin-2-ylamino) -benzoic acid

4.1 g (28.8 mmol) of E-1 was dissolved in 10 mL of diglyme (diethylene glycol dimethyl ether) and this solution was mixed with 4.79 g (34.6 mmol, 1.2 eq) of 4-aminobenzoic acid. The reaction mixture was refluxed for 16 hours. After cooling to room temperature, the precipitate was filtered with suction, washed with a small amount of diglyme, followed by diethyl ether, and dried under reduced pressure. 5.27 g (22.8 mmol, 79%) of E-2 was obtained as a colorless solid.
MS-ESI ⁺ : 232 (M + H) ⁺
E-3a) 4- (5-iodine-6-oxo-1,6-dihydro-pyrimidin-2-ylamino) -benzoic acid

9 g (38.9 mmol) E-2 was placed in 100 mL water and 2.18 g NaOH (54.5 mmol, 1.4 eq) was added. The solution was mixed with 11.9 g (46.7 mol, 1.2 eq) iodine and stirred at 65 ° C. for 3 hours. After cooling to 50 ° C., sodium thiosulfate pentahydrate was added to remove excess iodine, and the mixture was then stirred for an additional hour and cooled to room temperature. The brownish precipitate was filtered off with suction, washed with water and dried under reduced pressure. 13.7 g (38.4 mmol, 82%) of E-3a was obtained.
MS-ESI ⁺ : 358 (M + H) ⁺
E-3b) 4- (5-Bromo-6-oxo-1,6-dihydro-pyrimidin-2-ylamino) -benzoic acid

9 g (38.9 mmol) of E-2 was placed in 10 mL of acetic acid and to this was added dropwise a solution of 2.1 mL (40.9 mmol, 1.05 eq) of bromine in 50 mL of acetic acid and the mixture was allowed to cool at room temperature. Stir for about 1 hour. The reaction mixture was stirred in 800 mL of water, the precipitate was filtered off with suction, and the resulting brownish precipitate was washed with water and dried under reduced pressure. 11.5 g (37.1 mmol, 95%) of E-3b was obtained as a colorless solid.
R _f = 0.27 (silica gel, EE: MeOH 7: 3)
MS-ESI ⁺ : 309/311 (M + H) ⁺ (1 × Br)
E-4a) 4- (4-Chloro-5-iodo-pyrimidin-2-ylamino) -benzoyl chloride and
E-5a) 4- (4-Chloro-5-iodo-pyrimidin-2-ylamino) -benzoic acid

6.5 g (18.2 mmol) of E-3a was suspended in 80 mL of oxychloride and the mixture was refluxed for 3 hours with stirring. The reaction mixture was added dropwise to 800 mL of water / ice with vigorous stirring, stirred for an additional 30 minutes, and the crude acid chloride E-4a was filtered. This was dried under reduced pressure and used further without any purification.
To prepare the acid, the crude acid chloride was dissolved in 200 mL of THF and 200 mL of 20% NaHCaO ₃ aqueous solution was added. The reaction mixture was stirred at room temperature for 16 hours. The THF was removed under reduced pressure, the aqueous phase was adjusted to pH 2 with concentrated HCl, stirred for 10 minutes, the residue formed was suction filtered and washed with water. After drying under reduced pressure, 6.3 g (16.7 mmol, 92%) of E-5a was obtained as a colorless solid.
R _f = 0.24 (silica gel, ethyl acetate)
MS-ESI ⁺ : 427 (M + H) ⁺
E-4b) 4- (4-Chloro-5-bromo-pyrimidin-2-ylamino) -benzoyl chloride and
E-5b) 4- (4-Chloro-5-bromo-pyrimidin-2-ylamino) -benzoic acid

Prepared from E-3b in the same manner as the derivatives of E-4a and E-5a.
E-6b) [4- (5-Bromo-4-chloro-pyrimidin-2-ylamino) -phenyl]-(4-methyl-piperazin-1-yl) -methanone

559 mg (1.6 mmol) E-4b was dissolved in 5 mL THF and mixed with 414 μL (2.4 mmol, 1.5 eq) Hunig's base. 181 μL (1.6 mmol, 1 eq) N-methylpiperazine was added dropwise to this solution and the mixture was stirred at room temperature for 90 minutes. Next, 100 mL of water was added and the mixture was extracted three times with 50 mL of ethyl acetate. The mixed organic phase was dried over magnesium sulfate and the solvent was removed under reduced pressure. 566 mg (1.4 mmol, 86%) of E-6b was obtained in the form of a colorless resin.
MS-ESI ⁺ : 410/412 (M + H) ⁺ (1 × Br)
E-7b) (±)-(1S ^* , 2R ^* )-2- {5-bromo-2- [4- (4-methyl-piperazine-1-carbonyl) -phenylamino] -pyrimidin-4-ylamino} -Cyclopentanecarboxylic acid

459 mg (1.1 mmol) E-6b was dissolved in 5 mL 1-butanol and mixed with 536 μL (3.1 mmol, 2.8 eq) Hunig's base. 162 mg of cis-2-aminocyclopentane-carboxylic acid (racemic) was added to the solution and the reaction mixture was stirred at 110 ° C. for 100 minutes (CEM microwave, 100 W). The reaction mixture was evaporated, stirred in about 200 mL of water and extracted 3 times with 50 mL of ethyl acetate. The mixed organic phase was dried over magnesium sulfate and the solvent was removed under reduced pressure. 321 mg (0.64 mmol, 57%) of E-7b was obtained in the form of a colorless resin.
MS-ESI ⁺ : 503/505 (M + H) ⁺ (1 × Br)
E-8b) (±) -4- [5-bromo-4-((1R ^* , 2S ^* )-2-carbamoyl-cyclopentylamino) -pyrimidin-2-ylamino] -benzoic acid

1 g (3.04 mmol) of E-5b was dissolved in 3.9 mL of DMA and rooted with 1.3 μL (7.6 mmol, 1.5 eq) of Hunig's base. 390 mg (3.04 mmol, 1 eq) cis-2-aminocyclopentanecarboxamide (racemic) was added to the solution and the reaction mixture was stirred at 120 ° C. for 60 minutes. The reaction mixture was evaporated, the residue was taken up in 5 mL 1-butanol and the precipitate was filtered off with suction. After washing with 5 mL of cold 1-butanol and drying under reduced pressure, 935 mL (2.2 mmol, 73%) of E-8b was obtained in the form of a beige solid.
MS-ESI ⁺ : 420/422 (M + H) ⁺ (1 × Br)
Iodine derivative E-8a was similarly prepared from E-5a. However, the reaction temperature was 80 ° C.
E-9b) (±) -4- [4-((1R ^* , 2S ^* )-2-carbamoyl-cyclopentylamino) -5-cyano-pyrimidin-2-ylamino] -benzoic acid

935 mg (2.23 mmol) E-8b was dissolved in 8 mL DMF and 403 mg (4.45 mmol, 2 eq) copper (I) cyanide was added under argon. The yellow solution was mixed with 80 mg (0.067 mmol, 3 mol%) palladium-tetrakistriphenylphosphine and heated to 145 ° C. for 24 hours, during which about 50% of the educt was reacted. . The same amount of catalyst was added again and the mixture was heated for an additional 5 hours, then the reaction was worked up. The reaction mixture was filtered through a frit filled with silica gel (solvent: DMF) and the filtrate was evaporated to about 5 mL and poured into about 400 mL of distilled water. The formed precipitate was filtered, washed with 100 mL of water and dissolved in methanol. RP-gel was added and the solvent was removed under reduced pressure. The mixture was mixed in reverse phase (5% acetonitrile (+ 0.2% HCOOH) and 95% water (+ 0.2% HCOOH) to 50% acetonitrile (+ 0.2% HCOOH) and 50% water ( + 0.2% HCOOH)). 160 mg (0.44 mmol, 20%) of E-9b was isolated as a beige solid.
R _f = 0.30 (silica gel, CH ₂ Cl ₂ : MeOH: AcOH 5: 1: 0.1)
MS-ESI ⁺ : 367 (M + H) ⁺

Example 1
(±)-(1S ^* , 2R ^* )-2- {2- [4- (methyl-phenyl-sulfamoyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-ylamino} -cyclopentanecarbonamide ( Synthesis scheme A)
150 mg (0.6 mmol) A-2, 519 mg (1.98 mmol, 3 eq) 4-amino-N-methyl-N-phenyl-benzenesulfonamide and 130 μL (0.76 mmol, 1.15 eq) N-ethyldiisopropylamine Was dissolved in 3 mL of N, N-dimethylacetamide and the solution was stirred at 180 ° C. (heated in microwave) for 10 minutes. The solution was stirred in 30 mL of water, adjusted to pH 3 with 0.1 N HCl (aq), extracted three times with 10 mL of ethyl acetate, dried over magnesium sulfate, and volatile components were removed under reduced pressure. . The residue was purified by column chromatography (cyclohexane / ethyl acetate 2/1). 92 mg (0.2 mmol) of N-methyl-4- (4-methylsulfanyl-5-trifluoromethyl-pyrimidin-2-ylamino) -N-phenyl-benzenesulfonamide was obtained as a light brown solid.

85 mg (0.19 mmol) of this intermediate is dissolved in 7.5 mL of dichloromethane, 64 mg (0.285 mmol, 1.5 eq, 77%) of m-chloroperbenzoic acid is added and the mixture is stirred at room temperature for 3 hours. did. The organic phase was washed 3 times with 20 mL saturated aqueous NaHCaO ₃ solution, thus removing 3-chlorobenzoic acid. After drying the organic phase with sodium sulfate, 83 mg (0.18 mmol, 95%) of 4- (4-methanesulfinyl-5-trifluoromethyl-pyrimidin-2-ylamino) -N-methyl-N-phenyl- Benzenesulfonamide (A-4a) was obtained and used in the next step without further purification.
83 mg (0.18 mmol) A-4a, 26 mg cis-2-amino-1-cyclopentanecarboxamide (0.2 mmol, 1.1 eq, racemic) and 35 μL (0.2 mmol, 1.1 eq) Hunig's base Dissolved in DMA and stirred at 60 ° C. for 1 hour. The reaction mixture was stirred in 10 mL 0.1 N HCl (aq), the mixture was stirred for 30 min, the listed precipitate was filtered off with suction, washed with water and dried. Finally, purification was performed by column chromatography (cHex / EE 60/40 to 50/50 in 20 minutes). 43 mg (0.08 mmol, 45%) of compound 1 was obtained as a colorless solid.
(Examples 2 and 3) were prepared in the same manner.

Example 4
(±) -N-((1S ^* , 2R ^* )-2- {2- [4- (4-Methyl-piperazine-1-carbonyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-ylamino } -Cyclohexyl) -acetamide (Synthesis Scheme C)
38 mg (0.08 mmol) of C-3b was dissolved in 50 μL of DMA, 25 μL (0.16 mol, 2 eq) of Hunig's base was added, and dissolved at room temperature for several minutes. 5 μL of acetyl chloride (1 eq) was dissolved in a small amount of DMA and added dropwise to the reaction mixture. After about 10 minutes, the reaction mixture was taken up in dichloromethane and mixed with 10 mL of RP-gel and all volatile components were removed under reduced pressure. The mixture was purified by chromatography through the RP-phase (AcCN / water 5/95 to 95/5% over 20 minutes). The product fractions were combined and lyophilized to give 18 mg (0.034 mmol, 42%) of compound 4 as a colorless solid.
(Examples 5-12) were prepared in the same manner.

(Example 13)
(±) -1-methyl-3-((1S ^* , 2R ^* )-2- {2- [4- (4-methyl-piperazine-1-carbonyl) -phenylamino] -5-trifluoromethyl-pyrimidine -4-ylamino} -cyclohexyl) -urea (Synthesis Scheme C)
50 mg (0.105 mmol) of C-3b was dissolved in 50 μL of DMF and mixed with 55 μL (0.315 mmol, 3 eq) of Hunig's base. 6 μL of methyl isocyanate (1 eq) was added to this solution at room temperature. After about 10 minutes, the reaction mixture was taken up in dichloromethane and mixed with 10 mL of RP-gel and all volatile components were removed under reduced pressure. The mixture was purified by chromatography through the RP-phase (AcCN / water 5/95 to 95/5% over 20 minutes). The product fractions were combined and lyophilized to give 24 mg (0.045 mmol, 43%) of compound 13 as a colorless solid.
(Examples 14-17) were prepared in the same manner.

(Example 18)
Methyl ((±)-(1S ^* , 2R ^* )-2- {2- [4- (4-methyl-piperazine-1-carbonyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-ylamino} -Cyclohexyl) -carbamate (Synthesis Scheme C)
30 mg (0.063 mmol) of C-3b was dissolved in 50 μL of DMF and mixed with 22 μL (0.126 mmol, 2 eq) Hunig's base. 6 μL of methyl chloroformate (1.2 eq) was added to this solution at room temperature. After about 10 minutes, the reaction mixture was taken up in dichloromethane and mixed with 10 mL of RP-gel and all volatile components were removed under reduced pressure. The mixture was purified by chromatography through the RP-phase (AcCN / water 5/95 to 95/5% over 20 minutes). The product fractions were combined and lyophilized to give 13 mg (0.025 mmol, 39%) of compound 13 as a colorless solid.
(Examples 19 and 20) were prepared in the same manner.

(Example 21)
[4- (4-Cyclopentylamino-5-trifluoromethyl-pyrimidin-2-ylamino) -phenyl]-(4-methyl-piperazin-1-yl) -methanone (Synthesis Scheme C)
88 mg (0.22 mmol) of C-2a is dissolved in 290 μL of DMA, 26 μL (0.26 mmol, 1.2 eq) of cyclopentylamine and 75 μL (0.44 mmol, 2 eq) of Hunig base are added, and the reaction mixture is heated to 120 ° C. Until heated. After about 90 minutes, the reaction mixture was poured into about 10 mL of distilled water and the precipitate formed was filtered. The suspension is extracted three times with 20 mL ethyl acetate, the mixed organic phase is dried using saturated aqueous NaCl and magnesium sulfate, mixed with 100 μL dioxanic HCl, and all The volatile components of were removed under reduced pressure. 106 mg (0.219 mmol, 99%) of compound 21 were obtained in the form of the hydrochloride salt.
(Examples 22-26) were prepared similarly.

(Example 27)
(±)-(1S ^* , 2R ^* )-2- {2- [4- (4-Methyl-piperazine-1-carbonyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-ylamino} -cyclo Heptanecarboxylic acid dimethylamide (Synthesis Scheme C)
35 mg (0.067 mmol) of C-3d was dissolved in 250 μL of DMF and 30 μL (0.175 mmol, 2.6 eq) Hunig's base and finally 35 mg (0.11 mmol, 1.6 eq) TBTU were added. The reaction mixture was stirred at room temperature for 10 minutes and then mixed with 118 μL of dimethylamine (2M solution in THF, 0.235 mmol, 3.5 eq). The mixture was shaken at 35 ° C. for 4 hours, then the reaction mixture was taken up in acetonitrile and mixed with 6 mL RP-gel and all volatile components were removed under reduced pressure. Purification was performed by column chromatography through the RP-phase (12 min, acetonitrile / water 12/88 to 40/60). The product fraction was lyophilized to give 19 mg (0.035 mmol, 52%) of compound 27.
(Examples 28-30) were prepared in the same manner.

(Example 31)
(±) -4- [4-((1R ^* , 2S ^* )-2-isopropylcarbamoyl-cyclopentylamino) -5-trifluoromethyl-pyrimidin-2-ylamino] -N- [2- (1-methyl- Pyrrolidin-2-yl) -ethyl] -benzamide (Synthesis Scheme D)
Dissolve 80 mg (0.18 mmol) D-4c in 2.4 mL DMF, add 179 μL (1.03 mol, 1.5 eq) Hunig's base and mix the solution with 83 mg (0.25 mmol, 1.4 eq) TBTU. did. The solution was stirred at room temperature for 40 minutes, then 38.5 μL (0.27 mmol, 1.5 eq) of 2- (2-aminoethyl) -1-methylpyrrolidine was added and the mixture was stirred for 2 days. Next, silica gel was added to the reaction mixture and volatile components were removed under reduced pressure. Purification was performed by column chromatography through normal phase chromatography (DCm / MeOH / NH ₃ (aq) 5/1 / 0.1). 70 mg (0.125 mmol, 70%) of compound 31 was obtained.
(Examples 32-58) were prepared in the same manner.

(Example 59)
(±)-(1S ^* , 2R ^* )-2- {2- [4- (4-Methyl-piperazine-1-carbonyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-ylamino} -cyclo Pentanecarboxylic acid isopropylamide (Synthesis Scheme C)
88 mg (0.18 mmol) C-3d was dissolved in 2 mL DMF, 153 μL (0.90 mmol, 5 eq) Hunig's base was added and the solution was mixed with 81 mg (0.25 mmol, 1.4 eq) TBTU. The solution was stirred at room temperature for 20 minutes, then 12 μL (0.27 mmol, 1.5 eq) isopropylamine was added and the mixture was stirred for 16 hours. It was then filtered through basic aluminum oxide and washed with 20 mL methanol. RP gel was added to the filtrate and volatile components were removed under reduced pressure. The crude product immobilized on the RP-gel was reversed phase (95% water (+ 0.2% HCOOH) and 5% acetonitrile (+ 0.2% HCOOH) to 55% in 20 minutes. Of water and 45% acetonitrile). The corresponding product fraction was mixed with 1 eq of concentrated hydrochloric acid and the solvent was removed by lyophilization. 14 mg (0.025 mmol, 14%) of the hydrochloride salt of Compound 59 remained as a colorless film.
(Examples 60-69) were prepared similarly.
Examples 68 and 69 were chiral and were prepared in the same way from C-2a using the enantiomer of cis-2-aminocyclopentanecarboxylic acid to ultimately form isopropylamide. Alternatively, 68 and 69 may also be obtained from 59 by preparative chiral HPLC.

(Example 70)
(±)-(1S ^* , 2R ^* )-2- {2- [3-Chloro-4- (4-methyl-piperazine-1-carbonyl) -phenylamino] -5-trifluoromethyl-pyrimidine-4- Ilamino} -cyclopentanecarboxylic acid isopropylamide (Synthesis Scheme B)
30 mg (85.5 mmol) B-2a was dissolved in 100 μL NMP and 35 mg (0.14 mmol, 1.6 eq) (4-amino-2-chloro-phenyl)-(4-methyl-piperazine-1 Mixed with -yl) -methanone. 107 μL of 4M HCl in dioxane (0.43 mmol, 5 eq) was added to the reaction mixture and it was stirred at 5 ° C. for 12 hours. The reaction mixture is taken up in DCM / MeOH / NH ₃ 9/1 / 0.1, mixed with 6 mL of RP-gel, volatile components are removed in vacuo and the RP phase (5% acetonitrile to 95 in 10 min. Purified by chromatography through (% acetonitrile). The solvent was removed from the corresponding product fractions by lyophilization. 35 mg (0.06 mmol, 72%) of compound 70 remained.
(Examples 71-75) were prepared in the same manner.

Examples 76-105 (General Method)
1 eq of Compound B-4 (Compound E-8b for Examples 98-101 and Compound E-8a for Examples 102-105) was dissolved in DMF (about 1-10 mL per mmol) and 4-6 eq Hunig Base was added followed by 1.3-1.5 eq TBTU. The reaction mixture was stirred at room temperature for 10-30 minutes, then 1-1.5 eq of amine or aniline was added. After the reaction was completed, the reaction mixture was mixed with silica gel, all volatile components were removed under reduced pressure, and the product was purified and isolated by column chromatography (normal phase or RP-phase). .

(Example 106)
(±)-(3- [4-((1R ^* , 2S ^* )-2-carbamoyl-cyclopentylamino) -5-trifluoromethyl-pyrimidin-2-ylamino] -N-phenylbenzamide (Synthesis Scheme A)
700 mg (3.06 mmol) of A-3 was dissolved in 6 mL of DMA. 800 μL (4.6 mmol, 1.5 eq) Hunig's base was added and 440 mg of cis-2-amino-1-cyclopentanecarboxamide dissolved in 24 mL of DMA was added dropwise. The reaction mixture was stirred at room temperature. After 1 hour, diluted with 400 mL of dichloromethane and extracted twice with 200 mL of semi-saturated ammonium chloride solution, then dried over magnesium sulfate and the solvent removed under reduced pressure. 1.1 g of crude (±)-(1S ^* , 2R ^* )-2- (2-methylsulfanyl-5-trifluoromethyl-pyrimidin-4-ylamino) -cyclopentanecarboxamide remained as a beige solid . This was further reacted without purification.

For this, the solid was dissolved in 60 mL of THF, 1.31 g (5.5 mmol, 77% 2 eq) of mCPBA was added batchwise and the mixture was stirred at room temperature for 1 hour. The organic phase was washed 3 times with 20 mL saturated aqueous sodium bicarbonate solution, thus removing 3-chlorobenzoic acid. After drying the organic layer over magnesium sulfate, 1.15 g of crude (±)-(1S ^* , 2R ^* )-2- (2-methanesulfinyl-5-trifluoromethyl-pyrimidin-4-ylamino)- Cyclopentanecarboxamide was obtained and used in the next step without further purification.
150 mg (0.45 mmol) of (±)-(1S ^* , 2R ^* )-2- (2-methanesulfinyl-5-trifluoromethyl-pyrimidin-4-ylamino) -cyclopentanecarboxamide dissolved in 500 μL of NMP 148 mg (0.68 mmol, 1.5 eq) of m-aminobenzanilide was added. 34 μL of hydrochloric acid (4M solution in dioxane, 0.3 eq) was added to this solution and it was stirred at 50 ° C. for 16 hours. The reaction mixture was stirred in 30 mL water, adjusted to pH 3 with 10 mL 0.1 N HCl and extracted three times with 15 mL ethyl acetate. The mixed organic phase is dried over magnesium sulfate, all volatile constituents are removed under reduced pressure, the crude product is stirred in cyclohexane / ethyl acetate 60/40 and the precipitate is sucked off. Washed with filter paper, 2-propanol. 15 mg (0.03 mmol, 7%) of compound 106 was obtained as a colorless solid.
(Examples 107-109) were prepared similarly. Here, the purification was performed by column chromatography (ethyl acetate / cyclohexane, silica gel).

(Example 110)
(±)-((1S, 2R) -2- {5-bromo-2- [4- (4-methyl-piperazine-1-carbonyl) -phenylamino] -pyrimidin-4-ylamino} -cyclopentanecarboxylic acid Cyclopropylamide (Synthesis Scheme E)
39 mg (0.077 mmol) E-7b was dissolved in 500 μL DMF, 66 μL (0.39 mmol, 5 eq) Hunig's base and 35 mg (0.11 mmol).
1.4 eq) TBTU was added. The solution was stirred at room temperature for 20 minutes, then 8 μL (0.116 mmol, 1.5 eq) of cyclopropylamine was added and the mixture was left at room temperature overnight. It was filtered through basic aluminum oxide, washed with about 20 mL of methanol and the filtrate was mixed with 8 mL of RP-gel. After removing volatile components under reduced pressure, the mixture was reversed phase (95% water (+ 0.2% HCOOH) and 5% acetonitrile (+ 0.2% HCOOH) to 5% water and 95% over 20 minutes). Of acetonitrile). The solvent was removed from the corresponding product fractions by lyophilization. Compound 110 was obtained as a colorless film of 12 mg (0.021 mmol, 27%).
MS-ESI ⁺ : 542/544 (M + H) ⁺ (1Br)
(Examples 111-120) were prepared similarly.

(Example 121)
N-methyl-N- (1-methyl-piperidin-4-yl) -4- {4-[(±)-(1R ^* , 2S ^* )-2- (pyrrolidine-1-carbonyl) -cyclopentylamino]- 5-trifluoromethyl-pyrimidin-2-ylamino} -benzamide (Synthesis Scheme C)
80 mg (0.15 mmol) C-3e was dissolved in 1.4 mL DMF and 132 μL (0.77 mmol, 5 eq) Hunig's base and 69 mg (0.22 mmol, 1.4 eq) TBTU were added. The reaction mixture was stirred at room temperature for 30 minutes, then 119 μL (0.144 mmol, 9.4 eq) pyrrolidine was added and the mixture was stirred at room temperature for 16 hours. It was filtered through basic aluminum oxide, washed with about 20 mL of methanol and the filtrate was mixed with silica gel. After removing volatile components under reduced pressure, the mixture was purified by column chromatography (DCM / MeOH / NH ₃ 9/1 / 0.1). The product fraction was collected and then mixed with 100 μL of HCl (4M solution in dioxane), the solvent was removed under reduced pressure and 29 mg (0.048 mmol, 31%) of the hydrochloride salt of compound 121 was a colorless film Got as.
MS-ESI ⁺ : 574 (M + H) ⁺
(Examples 122-128) were prepared in the same manner.

(Example 129)
4- [4-((1R, 3S) -3-carbamoyl-cyclopentylamino) -5-trifluoromethyl-pyrimidin-2-ylamino] -N-methyl-N- (1-methyl-piperidin-4-yl) -Benzamide (Synthesis Scheme C)
75 mg (0.14 mmol) C-3f was dissolved in 1 mL DMF, 123 μL (0.7 mmol, 5 eq) Hunig's base was added and the reaction mixture was stirred for 30 min. Next, 14 μL (0.22 mmol, 1.5 eq) of aqueous ammonia (28%) was added and the mixture was stirred at room temperature for 5 hours. The solution is mixed with RP-gel, all volatile components are removed under reduced pressure, and the mixture is purified by column chromatography (10% acetonitrile (+ 0.2% HCOOH) and 90% water (+ 0.2% HCOOH) to 24% acetonitrile and 76% water). The product fraction was mixed with 100 μL of dioxane HCl and all volatile components were removed by lyophilization. 35 mg (0.063 mmol, 44%) of compound 129 was obtained in the form of the hydrochloride salt.
Example 130 was prepared in the same manner.

(Example 131)
(±)-(1S ^* , 2R ^* )-2- [2- (4-acetylamino-phenylamino) -5-trifluoromethyl-pyrimidin-4-ylamino] -cyclopentanecarboxylic acid isopropylamide (Synthesis Scheme D )
22 mg of D-6c was dissolved in 1 mL of THF, rooted with 14 μL (0.075 mmol, 1.5 eq) of Hunig's base, and then 3 μL of acetyl chloride dissolved in 500 μL of THF was added. After about 90 minutes, the reaction solution was diluted with 10 mL of methanol and 8 mL of RP-gel was added. Chromatographic purification was performed through reverse phase (78% water (+ 0.2% HCOOH) and 22% acetonitrile (+ 0.2% HCOOH) to 51% water and 49% acetonitrile over 15 minutes). Corresponding product fractions were mixed and the solvent was removed by lyophilization. 14 mg (0.028 mmol, 54%) of compound 131 was obtained.
(Examples 132-133) were prepared in the same manner.

(Example 134)
(±)-(1S ^* , 2R ^* )-2- {5-cyano-2- [4- (4-methyl-piperazine-1-carbonyl) -phenylamino] -pyrimidin-4-ylamino} -cyclopentanecarboxamide (Synthesis Scheme E)
40 mg (0.11 mmol) E-9b was dissolved in 1.5 mL DMF, 110 [mu] L (0.63 mmol, 5.8 eq) Hunig base was added and the reaction mixture was stirred for 40 min. Then 18 μL (0.16 mmol, 1.5 eq) N-methylpiperazine was added and the mixture was stirred at room temperature for 48 hours. The solution was mixed with silica gel, all volatile components were removed under reduced pressure, and the mixture was purified by column chromatography (DCM / MeOH 9/1). 33 mg (0.07 mmol, 67%) of compound 134 was obtained.
(Examples 135-136) were prepared in the same manner.

(Example 137)
(±)-(1S ^* , 2R ^* )-2- {5-cyclopropylethynyl-2- [4- (4-methyl-piperazine-1-carbonyl) -phenylamino] -pyrimidin-4-ylamino} -cyclo Pentanecarboxamide (Synthesis Scheme E)
50 mg (0.09 mmol) of 105 is dissolved in 220 μL of DMF, then 15 mg of dichloro-bis (triphenylphosphine) palladium (0.021 mmol, 23 mol%) and 10 mg (0.03 mmol, 0.58). eq) of copper (I) iodide was added. The solution was mixed with 320 μL Hunig's base and then 18 mg (0.27 mmol, 3 eq) ethylcyclopropane. The reaction mixture was filtered through silica gel with a mixture of DCM / MeOH / NH ₃ 4/1 / 0.1, then 6 mL of RP-gel was added. After removing volatile components, column through RP-phase (95% water (+ 0.2% HCOOH) and 5% acetonitrile (+ 0.2% HCOOH) to 50% water and 50% acetonitrile over 20 minutes) Purification by chromatography was performed. Corresponding product fractions were mixed and the solvent was removed by lyophilization. 32 mg (0.065 mmol, 71%) of compound 137 was obtained.
(Examples 138-139) were prepared in the same manner, but in Example 138 the reaction was performed at 40 ° C. in a propyne atmosphere in a nitrogen flask.

(Example 140)
(±) -4- [4-((1R ^* , 2S ^* )-2-carbamoyl-cyclopentylamino) -5-cyclopropyl-pyrimidin-2-ylamino] -N- (1-methyl-piperidin-4-yl ) -Benzamide (Synthesis Scheme E)
100 mg (0.15 mmol) 104 was suspended in 1.4 mL dioxane and 13 mg (0.15 mmol, 1 eq) cyclopropylboric acid was added. The solution was degassed under reduced pressure and 3.5 mg (0.004 mmol, 3 mol%) of dichloro [1,1′-bis (diphenylphosphino) -ferrocene] palladium (II) -dichloromethane adduct (PdCl ₂ dppf DCM) and 2 mL sodium carbonate solution (2M in water) were added under argon. The biphasic mixture was heated to 130 ° C. for 5 minutes (CEM microwave, 100 W). The organic phase was separated, diluted with methanol and mixed with 6 mL RP-gel. After removal of volatile components, column chromatography through reverse phase (97% water (+ 0.2% HCOOH) and 3% acetonitrile (+ 0.2% HCOOH) to 70% water and 30% acetonitrile over 12 minutes). Purification was performed by chromatography. The corresponding product fractions were mixed and the solvent was removed by lyophilization. 2 mg (0.003 mmol, 2%) of compound 140 was obtained.

(Example 141)
(±)-(1S ^* , 2R ^* )-2- [2- (4- [1.4] diazepan-1-yl-3-fluoro-phenylamino) -5-trifluoromethyl-pyrimidin-4-ylamino]- Cyclopentanecarboxylic acid isopropylamide (Synthesis scheme B)
23 mg (0.066 mmol) B-2a was dissolved in 100 μL NMP and 17 mg (0.079 mmol, 1.2 eq) 3-fluoro-4- (4-methyl- [1.4] diazepan-1-yl)- Phenylamine and finally 46 μL HCl (0.18 mmol, 2.8 eq, 4M solution in dioxane) was added. The reaction mixture was heated to 90 ° C. for 12 hours, mixed with 6 mL RP-gel and volatile components were removed under reduced pressure. Chromatographic purification was performed through the reverse phase (95% water (+ 0.2% HCOOH) and 5% acetonitrile (+ 0.2% HCOOH) to 55% water and 45% acetonitrile over 25 minutes). Corresponding product fractions were mixed and the solvent was removed by lyophilization. 3 mg (0.005 mmol, 8%) of compound 141 was obtained.

(Examples 142-144) were prepared in the same manner.

(Example 145)
(±)-(1R ^* , 2R ^* )-2- {2- [4- (4-Methyl-piperazine-1-carbonyl) -phenylamino] -5-trifluoromethyl-pyrimidin-4-ylamino} -cyclo Pentanecarboxamide (Synthesis Scheme C)
100 mg (0.25 mmol) C-2a was dissolved in 1 mL 1-butanol and this solution was dissolved in 35 mg (0.275 mmol, 1.1 eq) racemic trans-2-aminocyclopentanecarboxamide and 60 μL (0.35 mmol, 1.4 eq) Hunig base. The mixture was stirred at 110 ° C. (100 W, microwave CEM) for 30 minutes until complete conversion was obtained. About 20 mL of methanol was added to the reaction mixture, which was mixed with RP-gel (about 8 mL) and all volatile components were removed under reduced pressure. The mixture was filtered through an RP column (95% water (+ 0.2% HCOOH) and 5% acetonitrile (+ 0.2% HCOOH) to 55% water and 45% acetonitrile over 20 minutes). The corresponding product fraction was rooted with high concentration hydrochloric acid and the solvent was removed by lyophilization. 77 mg (0.146 mmol, 58%) of compound 145 was obtained as a colorless solid.
(Examples 146-147) were prepared analogously and Example 148 was prepared in the same way as Example 129 (starting from C-2a, nucleophilic substitution with β-amino acids and finally amide with ammonia Binding) was prepared.

In the examples, the biological activity of the compounds of the invention is described without limiting the invention to these examples.
As demonstrated by DNA staining followed by FACS analysis or Cellomics Array Scan analysis, the growth inhibition caused by the compounds of the present invention is mediated, inter alia, by errors in chromosome segregation. Due to the accumulation of incomplete separation, a large amount of ploidy occurs, which can eventually lead to growth inhibition or even apoptosis. Based on their biological properties, the compounds of general formula (I) according to the invention, their isomers and their physiologically acceptable salts are used for the treatment of diseases characterized by excessive or abnormal cell proliferation. Suitable for

(Example: Aurora B kinase assay)
A radioactive enzyme inhibition assay was constructed using a baculovirus-expressing recombinant human aurora B wild-type protein having a histidine (6) epitope (His-) at the N-terminal position, and the protein was infected with insect cells (SF21). Obtained from and purified.
Expression and Purification For this purpose, 300 × 10 ⁶ SF21 cells were incubated with an appropriate amount of baculovirus solution at 27 ° C. for 1 hour in the SF-900II insect cell culture (Invitrogen) (fern). Fernbach flask agitator, 50 rpm). Next, 250 mL of SF-900II culture solution was added and stirred for 3 days (100 rpm, 27 ° C.). Three hours before recovery, okadaic acid (C ₄₄ H ₆₈ O ₁₃ , Calbiochem # 495604) was added (final concentration 0.1 μM) to stabilize the phosphorylation site of recombinant Aurora B. The cells were pelleted by centrifugation (1000 rpm, 5 minutes, 4 ° C.), the supernatant was discarded, and the pellet was frozen in liquid nitrogen. The pellet was thawed (37 ° C., 5 minutes) and suspended in lysis buffer. 40 mL of lysis buffer (25 mM Tris / Cl, 10 mM MgCl ₂ , 300 mM NaCl, 20 mM imidazole, pH 8.0, 0.07% 2-mercaptoethanol and Roche Diagnostics complete protease inhibitor for 200 mL of the starting culture (Protease-Inhibitor-Complete)). After two rapid freeze / thaw cycles (liquid nitrogen at 37 ° C), the lysate is kept on ice for 30 minutes and then washed Ni-NTA beads (Ni-NTA Superflow Beads, 200 mL) (2 mL, 4 ° C.) and placed in an Econo-Pac column (Biorad # 732-1010). In all cases, 10 column volumes of wash buffer (25 mM Tris / Cl, 10 mM MgCl ₂ , 1000 mM NaCl, 20 mM imidazole, pH 8.0, 0.07% 2-mercaptoethanol and Roche Diagnostics protease inhibitors Complete after washing 5 times with (Protease-Inhibitor-Complete)) , elution buffer 8 mL (per starting culture of 200 mL) (25 mM Tris / Cl pH 8.0,300 mM NaCl, 10 mM MgCl 2, 0.03% Elution with Brij-35, 10% glycerol, 0.07% 2-mercaptoethanol, 400 mM imidazole). The mixed eluate fraction was desalted using a Sephadex G25 column and frozen buffer (50 mM Tris / Cl pH 8.0, 150 mM NaCl, 0.1 mM EDTA, 0.03% Brij-35, 10% glycerol, 1 mM DTT). )

(Kinase assay)
Test substances were placed in polypropylene dishes (96 wells, Greiner # 655 201) to cover a concentration window of 10 μM to 0.0001 μM. The final concentration of DMSO in the assay was 5%. 30 μL of protein mix (50 mM Tris / Cl pH 7.5, 25 mM MgCl ₂ , 25 mM, NaCl, 167 μL ATP, 200 ng His-Aurora B in freezing buffer) is provided in 25% DMSO Pipetted into 10 μL of test substance, which was incubated at room temperature for 15 minutes. Next, 10 μL of peptide mix (100 mM Tris / Cl pH 7.5, 50 mM MgCl ₂ , 50 mM NaCl, 5 μM NaF, 5 μM DTT, 1 μCi γ-P ³³ -ATP [Amersham], 50 μM substrate peptide [biotin -EPLERRLSLVPDS or its multimer, or biotin-EPLERRLSLVPKM or its multimer, or biotin-LRRWSLGLRRWSLGLRRWSLGLRRWSLG]). The reaction was incubated for 75 minutes (ambient temperature), stopped by adding 180 μL of 6.4% trichloroacetic acid and incubated on ice for 20 minutes. A multiscreen filtration plate (Millipore, MAIP NOB10) was first equilibrated with 100 μL 70% ethanol and then 180 μL trichloroacetic acid, and the liquid was removed using a suitable suction device. The kinase reaction that stopped the reaction was then applied. In each case, after washing 5 times with 180 μL of 1% trichloroacetic acid, the lower half of the dish was dried (at 55 ° C. for 10-20 minutes) and 25 μL of scintillation cocktail (Microscint, Packard # 6013611) was added. The incorporated γ-phosphate was quantified using a Wallac 1450 Microbeta Liquid Scintillation Counter. Samples with no test substance or substrate peptide were used as controls. IC ₅₀ values were obtained using Graph Pad Prism software.
The anti-proliferative activity of the compounds of the present invention was measured by proliferation tests and / or cell cycle analysis using cultured human tumor cells such as NCI-H460 tumor cells. In both test methods, the compounds showed good to very good activity, ie, for example, EC ₅₀ values in the NCI-H460 proliferation test of less than 5 μmol / L, generally less than 1 μmol / L.

(Measurement of growth inhibition in cultured human tumor cells)
To measure proliferation in cultured human tumor cells, the lung tumor cell line NCI-H460 (obtained from the American Type Culture Collection (ATCC)) in RPMI 1640 culture medium (Gibco) and 10% fetal calf serum (Gibco) Cultured and harvested in logarithmic growth phase. Next, the NCI-H460 cells were seeded in 96-well flat-bottom plates (Falcon) at a density of 1000 cells / well in RPMI 1640 culture medium and incubated overnight in an incubator (37 ° C., 5% CO ₂ ). The active substance was added to the cells at various concentrations (dissolved in DMSO; DMSO final concentration: 0.1%). After 72 hours of incubation, 20 μL of AlamarBlue reagent (AccuMed International) was added to each well and the cells were incubated for an additional 5-7 hours. After incubation, the color change of the AlamarBlue reagent was measured with a Wallac Microbeta fluorescence spectrophotometer. EC ₅₀ values were calculated using the Standard Levenburg Marquard algorithm (GraphPadPrizm). The cell cycle analysis was performed by using, for example, FACS analysis (fluorescence labeling cell sorter) or by cellomics array scan (CellCycle Analysis).

(FACS analysis)
Propidium iodide (PI) binds stoichiometrically to double-stranded DNA and thus measures the proportion of cells in the G1, S and G2 / M phases of the cell cycle based on cellular DNA content. Suitable for Cells in G0 and G1 phases have a diploid DNA content (2N), while G2 or mitotic cells have a DNA content of 4N.
For PI staining, for example, 1.75 × 10 ⁶ NCI-H460 cells are seeded on a 75 cm ² cell culture flask and 24 hours later, 0.1% DMSO is added as a control or the substance is added at various concentrations. (0.1% in DMSO). The cells were incubated with the substance or DMSO for 42 hours. Next, the cells were detached with trypsin and centrifuged. The cell pellet is washed with buffered saline solution (PBS), then the cells are permeabilized with Triton-X 100 (Sigma; 0.25% in PBS) for 5 minutes on ice, then in a 9: 1 ratio. Of propidium iodide (Sigma; 10 μg / mL) and RNAse (RNAse) (Serva; 1 mg / mL) for at least 20 minutes in the dark. The DNA measurement was performed with a Becton Dickinson FACS analyzer equipped with an argon laser (500 mW, emission 488 nm), and data was acquired and evaluated using the DNA Cell Quest Program (BD).

(Cellomics Array Scan)
NCI-H460 cells were seeded in a 96-well flat bottom dish (Falcon) at a density of 2000 cells / well in RPMI 1640 medium (Gibco) containing 10% fetal calf serum (Gibco) and incubated in an incubator (37 ° C, Incubate overnight in 5% CO ₂ ). The active substance was added to the cells at various concentrations (dissolved in DMSO; DMSO final concentration: 0.1%). After 42 hours of incubation, the culture medium is filtered off with suction and the cells are fixed with 4% formaldehyde and Triton X-100 (1: 200 in PBS) for 10 minutes at ambient temperature and simultaneously permeabilized, then 0.3. Washed twice with% BSA solution (Calbiochem). The DNA was then stained by adding 50 μL / well of 4 ′, 6-diamidino-2-phenyliodol (DAPI; Molecular Probes) at a final concentration of 300 nM for 1 hour at ambient temperature in the dark. The preparation is then carefully washed twice with PBS, the plate is placed down with a black adhesive film, analyzed with a Cellomics ArrayScan using the CellCycle BioApplication program, and visualized with Spotfire. And evaluated.
The substance of the present invention was an Aurora kinase inhibitor. Based on their biological properties, the compounds of general formula (I) according to the invention, their isomers and their physiologically acceptable salts are suitable for diseases characterized by excessive or abnormal cell proliferation. Suitable for treatment.

Such diseases include, for example, viral infections (eg, HIV and Kaposi's sarcoma); inflammatory and autoimmune diseases (eg, colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacteria Infectious diseases, fungal infections and / or parasitic infections; leukemias, lymphomas and solid tumors (eg carcinoma and sarcomas), skin diseases (eg psoriasis); hyperplasia characterized by an increased number of cells Diseases (eg fibroblasts, hepatocytes, bone cells, bone marrow cells, chondrocytes, smooth muscle cells or epithelial cells (eg endometrial hyperplasia)); bone diseases and cardiovascular diseases (eg Restenosis and hypertrophy).
For example, but not limited to, the following cancers may be treated with the compounds of the invention: eg brain tumors (eg acoustic schwannoma, astrocytoma (eg ciliary cell astrocytoma, fibrotic) Astrocytoma, protoplasmic astrocytoma, such as astrocytoma, undifferentiated astrocytoma and glioblastoma, brain lymphoma, brain metastasis ( brain metastases, hypophyseal tumors (such as prolactinoma, HGH (human growth hormone) producing tumors and ACTH producing tumors (adrenocorticotropic hormone)), craniopharyngioma, medulloblastoma, meninges Neural tumors (neoplasms) (eg, autonomic nervous system tumors (eg, neuroblastoma sympathicum), gangliomas, paragangliomas (such as Pheochromocytoma, chromium Histological tumors) (such as brain tumors and bone marrow tumors); intestinal cancers (eg rectum, colon, anus, small intestine and duodenum) Eyelid tumor (such as basal cell carcinoma or basal cell carcinoma); pancreatic cancer or pancreatic carcinoma (carcinoma); bladder cancer or bladder carcinoma; lung cancer (bronchial cancer) (Eg, small cell bronchial carcinoma (oat cell carcinoma) and non-small cell bronchial carcinoma (eg, plate epithelial carcinoma, adenocarcinoma and large cell carcinoma)); breast cancer (eg, Mammary carcinoma (such as invasive ductal carcinoma, collagenous carcinoma, invasive lobular carcinoma, tubular adenocarcinoma, adenoid cystic carcinoma and papillary carcinoma); non-Hodgkin lymphoma (NHL) (eg, bar Kit lymphoma, low-grade non-Hodgkin lymphoma (Such as NHL and mycosis fungoides); uterine cancer, endometrial cancer or endometrial cancer; CUP syndrome (unknown primary cancer); ovarian cancer or ovarian carcinoma (eg of Kratzkin tumor) Testicular cancer (eg, seminoma and non-seminoma); lymphoma (lymphosarcoma) (eg, malignant lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (NHL) (chronic lymphocytic leukemia, leukoreticuloendotheliosis) Immunocytoma, plasmacytoma (multiple myeloma), immunoblastoma, Burkitt lymphoma, T-zone mycosis fungoides, large cell anaplastic lymphoblastoma and Laryngeal cancer (such as vocal cord, upper glottis, glottis and lower glottic laryngeal tumor); bone cancer (such as osteochondroma, chondroma, chondroblastoma, cartilage) Myx fibromas, osteomas, osteoid osteomas , Osteoblastoma, eosinophilic granuloma, giant cell tumor, chondrosarcoma, osteosarcoma, Ewing sarcoma, reticulosarcoma, plasmacytoma, giant cell tumor, fibrous dysplasia, juvenile bone cyst and artery Head and neck tumors (such as lip, tongue, floor of mouth, oral cavity, gingiva, palate, salivary gland, pharynx, nasal cavity, sinuses, larynx and middle ear tumor); For example, liver cell carcinoma or hepatocellular carcinoma (HCC)); leukemia (eg, acute leukemia (eg, acute lympho / lymphoblastic leukemia (ALL), acute bone marrow) Chronic leukemia (such as chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML)); stomach cancer or gastric carcinoma (For example, papillary adenocarcinoma, tubular adenocarcinoma and mucinous adenocarcinoma, signet ring cell carcinoma, glandular flatness Melanoma (such as superficially spreading nodular malignant melanoma and terminal melanoma), such as epithelial cancer, small cell carcinoma and undifferentiated cancer; kidney Cancer (eg, renal cell carcinoma or adrenal gland tumor or Grawitz's tumor); esophageal cancer or carcinoma; penile cancer; prostate cancer; pharyngeal cancer or carcinoma (eg, carcinoma) Retinoblastoma; eg, vaginal or vaginal carcinoma; plate epithelial carcinoma, adenocarcinoma, carcinoma in situ (such as nasopharyngeal cancer, oropharyngeal cancer and hypopharyngeal cancer) in situ carcinoma), malignant melanoma and sarcoma; thyroid cancer (such as papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer and anaplastic carcinoma); spine cell carcinoma, epidermoid carcinoma of the skin (Epidormoid carcinoma) and Squamous cell carcinoma (plate epithelial carcinoma); thymoma, such as cancer of the urethra cancer and vulva and the like.

The novel compounds may be used for the prevention or short-term or long-term treatment of the above-mentioned diseases, as well as radiation therapy or other modern compounds such as cytostatic or cytotoxic substances, cell growth inhibition You may use it in combination with an agent, an antiangiogenic substance, a steroid, or an antibody.
The compounds of the general formula (I) may be used alone or in combination with other active substances of the present invention, and if necessary, active substances having other pharmacological activities And may be used in combination.

  Chemotherapeutic agents that may be administered in combination with the compounds of the present invention include hormones, hormone analogs and antihormonal agents (eg, tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, Aminoglutethimide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors (eg, anastrozole, letrozole, riarosol, borozole, exemestane, atamestane) , LHRH agonists and antagonists (eg goserelin acetate, leuprolide), growth factor inhibitors (eg “platelet-derived growth factor” and “hepatocyte growth factor”) Inhibitors include, for example, “growth factor” antibodies, “growth factor receptor” antibodies and tyrosine kinase inhibitors such as gefitinib, imatinib, lapatinib, and trastuzumab); antimetabolites (eg, methotrexate) , Antifolates such as raltitrexed, pyrimidine analogs such as 5-fluorouracil, capecitabine and gemcitabine, mercaptopurine, thioguanine, cladribine and pentostatin, purines and adenosine analogs such as cytarabine and fludarabine); antitumor antibiotics (Eg, anthracyclines such as doxorubicin, daunorubicin, epirubicin and idarubicin, mitomycin C, bleomycin, dactinomycin, pricamycin, streptozocin); Platinum derivatives (eg cisplatin, oxaliplatin, carboplatin); alkylating agents (eg estramustine, mechlorethamine, melphalan, chlorambucil, busulfan, dacarbazine, cyclophosphamide, ifosfamide, temozolomide, eg carmustine and Nitrosourea such as lomustine, thiotepa); mitotic inhibitors (eg, vinca alkaloids such as vinblastine, vindesine, vinorelbine and vincristine; and taxanes such as paclitaxel, docetaxel); topoisomerase inhibitors (eg, etoposide and Epipodophyllotoxin such as etopophos, teniposide, amsacrine, topotecan, irinotecan, mitoxantrone) and, for example, Chin, anagrelide, clodronate, filgrastim, interferon alpha, leucovorin, rituximab, procarbazine, levamisole, mesna, mitotane, but include various chemotherapeutic agents, such as pamidronate and porfimer, but are not limited to.

Examples of suitable formulations are tablets, capsules, suppositories, solutions, especially for injection (subcutaneous (sc), intravenous (iv), intramuscular (im)) and infusion solutions Elixirs, emulsions or dispersible powders. The content of the pharmaceutically active compound or compounds as a whole is in the range of 0.1 to 90 wt.%, Preferably 0.5 to 50 wt.% Of the composition, in other words the dosage range specified below. Should be sufficient to do. The specified dose may be given several times a day if necessary.
Suitable tablets are, for example, the active substance (s) known ingredients, e.g. inert diluents such as calcium carbonate, calcium phosphate or lactose, tablet disintegrants such as corn starch or alginic acid Acquired by mixing with binders such as starch or gelatin, lubricants such as magnesium stearate or talc and / or substances that delay release such as carboxymethyl cellulose, cellulose acetate phthalate or polyvinyl acetate May be. The tablet may also include multiple layers.

  Coated tablets may be prepared by coating the center to be prepared with a substance usually used for tablet coating, such as Kollidon or shellac, gum arabic, talc, titanium dioxide or sugar. . In order to achieve delayed release or to prevent incompatibility, the center may be composed of several layers. Similarly, the tablet coating may be composed of several layers, thereby achieving delayed release and optionally using the excipients described above in the tablets.

Syrups or elixirs containing the active substances according to the invention or combinations thereof are additionally sweeteners such as saccharin, cyclamic acid, glycerol or sugar and flavorings such as flavourings such as vanillin or orange extract ( flavor enhancer). They also contain thickening agents such as suspension adjuvants or sodium carboxymethylcellulose, for example wetting agents such as condensates of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoate. May be included.
Liquids for injection and infusion are added by conventional methods, for example, isotonic agents, preservatives such as p-hydroxybenzoate, or stabilizers such as alkali metal salts of ethylenediaminetetraacetic acid. Emulsifiers and / or dispersants may be used, whereas when water is used as a diluent, for example, an organic solvent is used as a solvating agent or solubilizer, and an injection vial or ampoule or infusion. Prepare by transferring to a bottle.

Capsules containing one or more active substances or combinations of active substances may be prepared, for example, by mixing the active substance with an inert carrier such as lactose or sorbitol and packing them into gelatin capsules.
Suitable suppositories may be prepared for example by mixing with carriers provided for this purpose, such as neutral fats or polyethylene glycol or derivatives thereof.
Examples of excipients that may be used include water, paraffin (eg petroleum fraction), vegetable oil (eg peanut oil or sesame oil), monofunctional or polyfunctional alcohols (eg ethanol or glycerol) Pharmaceutically acceptable organic solvents, natural mineral powders (eg, kaolin, clay, talc, chalk), synthetic mineral powders (eg, highly dispersed silicic acid and silicates), sugars (eg, Carriers such as sucrose, lactose and glucose), emulsifiers (eg lignin, spent sulphite liquor, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (eg magnesium stearate, talc, stearic acid and Sodium lauryl sulfate).

The formulation is administered by conventional methods, preferably by the oral or transdermal route, most preferably by the oral route. For oral administration, in addition to the tablets as well as the above-mentioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate, and various additions such as starch, preferably potato starch, gelatin, etc. It may be included with things. In addition, lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used simultaneously for the tablet manufacturing process. In the case of an aqueous suspension, the active substance may be mixed with various flavor enhancers or colorants in addition to the excipients described above.
For parenteral use, a solution of the active substance may be used with a suitable liquid carrier.
The dosage for intravenous administration is 1-1000 mg per hour, preferably 5-500 mg per hour.
However, the dosage may need to deviate occasionally from the stated amounts depending on body weight, route of administration, individual reactivity to the drug, the nature of the formulation and the time or interval at which the drug is administered. Thus, in some cases it may be sufficient to use less than the above-mentioned minimum dose, while in other cases it may be necessary to exceed the upper limit. For large doses, it may be desirable to divide into several smaller doses that span the day.

The following examples of such formulations illustrate the invention without limiting the scope of the invention.
(Example of pharmaceutical formulation)
A) 1 tablet per tablet

Active substance 100 mg
Lactose 140 mg
Corn starch 240 mg
Polyvinylpyrrolidone 15 mg
Magnesium stearate 5 mg

500 mg

The finely ground active substance, lactose and some corn starch were mixed together. The mixture was sieved and then wetted with a solution of polyvinylpyrrolidone in water, kneaded, granulated wet and dried. The granules, the remaining corn starch and magnesium stearate were screened and mixed together. The mixture was pressed to produce tablets of appropriate shape and size.

B) Per tablet

Active substance 80 mg
Lactose 55 mg
Corn starch 190 mg
Microcrystalline cellulose 35 mg
Polyvinylpyrrolidone 15 mg
Sodium-carboxymethyl starch 23 mg
Magnesium stearate 2 mg

400 mg

Mix the finely ground active substance, some corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone together, screen the mixture and work with the remaining corn starch and water to form granules that are dried And sifted. Sodium carboxymethyl starch and magnesium stearate were added and mixed, and the mixture was pressed to form tablets of the appropriate size.

C) Ampoule solution

Active substance 50 mg
Sodium chloride 50 mg
Water for inj. 5 ml

The active substance was dissolved in water at its own pH or optionally at pH 5.5-6.5 and sodium chloride was added to make the solution isotonic. The resulting solution was filtered to make it pyrogen-free and the filtrate was transferred aseptically to an ampoule which was then sterilized and sealed with a fusion. The ampoule contained 5 mg, 25 mg and 50 mg of active substance.

(Bibliography)
Adams, RR, Wheatley, SP, Gouldsworthy, AM, Kandels-Lewis, SE, Carmena, M., Smythe, C., Gerloff, DL, and Earnshaw, WC (2000). INCENP binds the Aurora-related kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage furrow.Curr. Biol. 10, 1075-1078.

Andrews, PD, Knatko, E., Moore, WJ, and Swedlow, JR (2003). Mitotic mechanics: the auroras come into view. Curr. Opin. Cell Biol. 15, 672-683.

Bayliss, R., Sardon, T., Vernos, I., And Conti, E. (2003). Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. Cell 12, 851-862.

Bischoff, JR, Anderson, L., Zhu, Y., Mossie, K., Ng, L., Souza, B., Schryver, B., Flanagan, P., Clairvoyant, F., Ginther, C., Chan , CS, Novotny, M., Slamon, DJ, and Plowman, GD (1998) .A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers.EMBO J. 17, 3052-3065.

Bishop, JD and Schumacher, JM (2002) .Phosphorylation of the carboxyl terminus of inner centromere protein (INCENP) by the Aurora B Kinase stimulates Aurora B kinase activity.J. Biol. Chem. 277, 27577-27580.

Bolton, MA, Lan, W., Powers, SE, McCleland, ML, Kuang, J., And Stukenberg, PT (2002) .Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol. Biol. Cell 13, 3064-3077.

Carmena, M. And Earnshaw, WC (2003) .The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. 4, 842-854.

Csomos, P., Bernath, G., And Fueloep, F. (2002). A novel preparation of 2-aminocyclopentanecarboxamides. Monatsh. Chem., 133 (8), 10771084

Ditchfield, C., Johnson, VL, Tighe, A., Ellston, R., Haworth, C., Johnson, T., Mortlock, A., Keen, N., And Taylor, SS (2003). Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.J. Cell Biol. 161, 267-280.

Eyers, PA and Maller, JL (2004) .Regulation of Xenopus Aurora A activation by TPX2. J. Biol. Chem. 279, 9008-9015.

Forro, E., and Fueloep, F. (2003) Lipase-Catalyzed Enantioselective ring Opening of Unactivated Alicyclic-Fused β-Lactams in an Organic Solvent.Org. Lett. 5, 1209-1211.

Glover, DM, Hagan, IM, and Tavares, AA (1998) .Polo-like kinases: a team that plays throughout mitosis. Genes Dev. 12, 3777-3787.

Gorbsky, GJ (2004). Mitosis: MCAK under the aura of Aurora B. Curr. Biol. 14, R346-R348.

Gruneberg, U., Neef, R., Honda, R., Nigg, EA, and Barr, FA (2004) .Relocation of Aurora B from centromeres to the central spindle at the metaphase to anaphase transition requires MKlp2. J. Cell Biol 166, 167-172.

Hauf, S., Cole, RW, LaTerra, S., Zimmer, C., Schnapp, G., Walter, R., Heckel, A., Van Meel, J., Rieder, CL, and Peters, JM (2003 ) .The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint.J. Cell Biol. 161, 281-294.

Hirota, T., Kunitoku, N., Sasayama, T., Marumoto, T., Zhang, D., Nitta, M., Hatakeyama, K., And Saya, H. (2003). Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells.Cell 114, 585-598.

Honda, R., Korner, R., and Nigg, EA (2003) .Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol. Biol. Cell 14, 3325-3341.

Kaitna, S., Mendoza, M., Jantsch-Plunger, V., and Glotzer, M. (2000). Incenp and an aurora-like kinase form a complex essential for chromosome segregation and efficient completion of cytokinesis. Curr. Biol. 10, 1172-1181.

Katayama, H., Ota, T., Jisaki, F., Ueda, Y., Tanaka, T., Odashima, S., Suzuki, F., Terada, Y., and Tatsuka, M. (1999). Mitotic kinase expression and colorectal cancer progression. J. Natl. Cancer Inst. 91, 1160-1162.

Keen, N. and Taylor, S. (2004). Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4, 927-936.

Kufer, TA, Sillje, HH, Korner, R., Gruss, OJ, Meraldi, P., and Nigg, EA (2002). Human TPX2 is required for targeting Aurora-A kinase to the spindle. J. Cell Biol. 158 617-623.

Lane, HA and Nigg, EA (1996). Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J. Cell Biol. 135, 1701-1713.

Li, X., Sakashita, G., Matsuzaki, H., Sugimoto, K., Kimura, K., Hanaoka, F., Taniguchi, H., Furukawa, K., and Urano, T. (2004). Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-CJ Biol. Chem. 279, 47201-47211.

Mayer, TU, Kapoor, TM, Haggarty, SJ, King, RW, Schreiber, SL, and Mitchison, TJ (1999) .Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype based screen.Science 286, 971-974.

Meraldi, P., Honda, R., and Nigg, EA (2004). Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr. Opin. Genet. Dev. 14, 29-36.

Murata-Hori, M. And Wang, YL (2002) .The kinase activity of aurora B is required for kinetochore-microtubule interactions during mitosis. Curr. Biol. 12, 894-899.

Nigg, EA (2001). Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2, 21-32.

Nishio, K., Ishida, T., Arioka, H., Kurokawa, H., Fukuoka, K., Nomoto, T., Fukumoto, H., Yokote, H., and Saijo, N. (1996). Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.Anticancer Res. 16, 3387-3395.

Nurse, P. (1990). Universal control mechanism regulating onset of M-phase.Nature 344, 503-508.

Ota, T., Suto, S., Katayama, H., Han, ZB, Suzuki, F., Maeda, M., Tanino, M., Terada, Y., and Tatsuka, M. (2002). Increased mitotic phosphorylation of histone H3 attributable to AIM-1 / Aurora-B overexpression contributes to chromosome number instability.Cancer Res. 62, 5168-5177.

Qian, YW, Erikson, E., Taieb, FE, and Maller, JL (2001) .The polo-like kinase Plx1 is required for activation of the phosphatase Cdc25C and cyclin B-Cdc2 in Xenopus oocytes. Mol. Biol. Cell 12 , 1791-1799.

Sasai, K., Katayama, H., Stenoien, DL, Fujii, S., Honda, R., Kimura, M., Okano, Y., Tatsuka, M., Suzuki, F., Nigg, EA, Earnshaw, WC, Brinkley, WR, and Sen, S. (2004). Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil. Cytoskeleton 59, 249-263.

Satinover, DL, Leach, CA, Stukenberg, PT, and Brautigan, DL (2004) .Activation of Aurora-A kinase by protein phosphatase inhibitor-2, a bifunctional signaling protein.Proc. Natl. Acad. Sci. US A 101, 8625-8630.
Schiff, PB and Horwitz, SB (1980). Taxol stabilizes microtubules in mouse fibroblast cells.Proc. Natl. Acad. Sci. US A 77, 1561-1565.

Vigneron, S., Prieto, S., Bernis, C., Labbe, JC, Castro, A., and Lorca, T. (2004). Kinetochore localization of spindle checkpoint proteins: who controls whom? Mol. Biol. Cell 15 , 4584-4596.

Zhou, H., Kuang, J., Zhong, L., Kuo, WL, Gray, JW, Sahin, A., Brinkley, BR, and Sen, S. (1998). Tumour amplified kinase STK15 / BTAK induces centrosome amplification , aneuploidy and transformation. Nat. Genet. 20, 189-193.

Claims (15)

The compound of general formula (1), which may be in its tautomeric form, its racemic form, its enantiomeric form, its diastereomeric form or a mixture thereof, and is pharmaceutically acceptable Such compounds, which may be in the form of their acid addition salts.

(Where
R ¹ means a group selected from C _3-10 -cycloalkyl and 3- to 8-membered heterocycloalkyl, R ⁵ as a substituent, and one or more R ⁴ As a substituent group;
R ² is selected from C _1-6 -alkyl, C _3-10 -cycloalkyl, 3 to 8 membered heterocycloalkyl, C _6-15 -aryl and 5 to 12 membered heteroaryl. Meaning a group, optionally having one or more R ⁴ as substituents;
R ³ is hydrogen, halogen, —CN, —NO ₂ , C _1-4 -alkyl, C _1-4 -haloalkyl, C _3-10 -cycloalkyl, C _4-16 -cycloalkylalkyl and C _7-16. Means a group selected from among arylalkyl;
R ⁴ means a group selected from R ^a , R ^b and R ^a having one or more of the same or different R ^c and / or R ^b as substituents;
R ⁵ is —C (O) R ^c , —C (O) NR ^c R ^c , —S (O) ₂ R ^c , —N (R ^f ) S (O) ₂ R ^c , —N (R ^f ) Means a group selected from C (O) R ^c , —N (R ^f ) C (O) OR ^c, and —N (R ^f ) C (O) NR ^c R ^c ;
Each of R ^a is C _1-6 -alkyl, C _3-10 -cycloalkyl, C _4-16 -cycloalkylalkyl, C _6-10 -aryl, C _7-16 -arylalkyl, 2 to 6 members Heteroalkyl, 3 to 8 membered heterocycloalkyl, 4 to 14 membered heterocycloalkylalkyl, 5 to 12 membered heteroaryl and 6 to 18 membered heteroarylalkyl independently of each other Selected;
Each of R ^b is a suitable group: ═O, —OR ^c , C _1-3 -haloalkyloxy, —OCF ₃ , —S, —SR ^c , ═NR ^c , ═NOR ^c , —NR ^c R ^c , halogen, —CF ₃ , —CN, —NC, —OCN, —SCN, —NO ₂ , —S (O) R ^c , —S (O) ₂ R ^c , —S (O) ₂ OR ^c , ^{-S (O) NR c R c} , -S (O) 2 NR c R c, -OS (O) R c, -OS (O) 2 R c, -OS (O) 2 OR c, -OS ( O) ₂ NR ^c R ^c , —C (O) R ^c , —C (O) OR ^c , —C (O) NR ^c R ^c , —CN (R ^f ) NR ^c R ^c , —CN (OH) R ^c , —CN (OH) NR ^c R ^c , —OC (O) R ^c , —OC (O) OR ^c , —OC (O) NR ^c R ^c , —OCN (R ^f ) NR ^c R ^c , ^{-N (R f) C (O} ) R c, -N (R f) C (S) R c, -N (R f) S (O) 2 R c, -N (R f) C (O) OR ^c , —N (R ^f ) C (O) NR ^c R ^c , — [N (R ^f ) C (O)] ₂ R ^c , —N [C (O)] ₂ R ^c , _{-N [C (O)] 2} OR c, - [N (R f) C (O)] 2 OR c and ^{-N (R f) CN (R} f) independently of each other from among the NR ^c R ^c Selected;
Each R ^c is independently of the other hydrogen or C _1-6 -alkyl, C _3-10 -cycloalkyl, C _4-11 -cycloalkylalkyl, C _6-10 -aryl, C _7-16 -arylalkyl 2 to 6 membered heteroalkyl, 3 to 8 membered heterocycloalkyl, 4 to 14 membered heterocycloalkylalkyl, 5 to 12 membered heteroaryl and 6 to 18 membered heteroarylalkyl. A group selected from the above, and optionally having one or more of the same or different R ^d and / or R ^e as a substituent;
Each R ^d is independently of one another hydrogen or C _1-6 -alkyl, C _3-8 -cycloalkyl, C _4-11 -cycloalkylalkyl, C _6-10 -aryl, C _7-16 -arylalkyl 2 to 6 membered heteroalkyl, 3 to 8 membered heterocycloalkyl, 4 to 14 membered heterocycloalkylalkyl, 5 to 12 membered heteroaryl and 6 to 18 membered heteroarylalkyl. A group selected from the above, and optionally having one or more of R ^e and / or R ^f as substituents;
Each of R ^e is a suitable group: ═O, —OR ^f , C _1-3 -haloalkyloxy, —OCF ₃ , ═S, —SR ^f , ═NR ^f , ═NOR ^f , —NR ^f R ^f , halogen, —CF ₃ , —CN, —NC, —OCN, —SCN, —NO ₂ , —S (O) R ^f , —S (O) ₂ R ^f , —S (O) ₂ OR ^f , ^{-S (O) NR f R f} , -S (O) 2 NR f R f, -OS (O) R f, -OS (O) 2 R f, -OS (O) 2 OR f, -OS ( O) ₂ NR ^f R ^f , —C (O) R ^f , —C (O) OR ^f , —C (O) NR ^f R ^f , —CN (R ^g ) NR ^f R ^f , —CN (OH) R ^f , —C (NOH) NR ^f R ^f , —OC (O) R ^f , —OC (O) OR ^f , —OC (O) NR ^f R ^f , —OCN (R ^g ) NR ^f R ^f , ^{-N (R g) C (O} ) R f, -N (R g) C (S) R f, -N (R g) S (O) 2 R f, -N (R d) C (O) OR ^f , -N (R ^g ) C (O) NR ^f R ^f and -N (R ^g ) CN (R ^f ) NR ^f R ^f Selected independently of each other;
Each R ^f is independently of one another hydrogen or C _1-6 -alkyl, C _3-8 -cycloalkyl, C _4-11 -cycloalkylalkyl, C _6-10 -aryl, C _7-16 -arylalkyl 2 to 6 membered heteroalkyl, 3 to 8 membered heterocycloalkyl, 4 to 14 membered heterocycloalkylalkyl, 5 to 12 membered heteroaryl and 6 to 18 membered heteroarylalkyl. A group selected from the above, and may have one or more of the same or different R ^g as a substituent;
Each R ^g is independently of the other hydrogen, C _1-6 -alkyl, C _3-8 -cycloalkyl, C _4-11 -cycloalkylalkyl, C _6-10 -aryl, C _7-16 -arylalkyl 2 to 6 membered heteroalkyl, 3 to 8 membered heterocycloalkyl, 4 to 14 membered heterocycloalkyl, 5 to 12 membered heteroaryl or 6 to 18 membered heteroarylalkyl . ) The compound according to claim 1, wherein R ³ represents a group selected from halogen and C _1-4 -haloalkyl. R ³ means a -CF _3, compound of claim 2. The R ^{2 according} to any one of claims 1 to 3, which means C _6-10 -aryl or 5- to 12-membered heteroaryl optionally having one or more R ⁴ as a substituent. Compound. The compound according to claim 4, wherein R ² represents phenyl optionally having one or more R ⁴ as a substituent. Compound of general formula (1A).

(Where
n is 0 or 1;
m is 1-5,
y is 0-6,
The remaining groups are as defined in claim 1. ) R ³ is halogen and C _1-4 - denotes a group selected from among haloalkyl, compound of claim 6. R ³ means a -CF _3, claim 7 compound according. 9. The process according to claim 6, wherein R ² represents C _6-10 -aryl or a 5- to 12-membered heteroaryl optionally having one or more R ⁴ as a substituent. Compound. R ² means a phenyl which may have as a substituent one or more R ^4, any one compound according to claim 6-9.   The compound according to any one of claims 1 to 10 or a pharmaceutically active salt thereof for use as a pharmaceutical composition.   11. The compound according to any one of claims 1 to 10 or a pharmaceutically active salt thereof for preparing a pharmaceutical composition having antiproliferative activity.   A compound of the general formula (1) or (1A) according to any one of claims 1 to 10 or one or more of physiologically acceptable salts thereof as an active substance, Pharmaceuticals that may contain excipients and / or carriers.   The general formula (1) or (1A) according to any one of claims 1 to 10, for preparing a pharmaceutical composition for the treatment and / or prevention of cancer, infectious diseases, inflammatory diseases and autoimmune diseases. Use of the compound.   11. A compound of general formula (1) or (1A) according to any one of claims 1 to 10, wherein its tautomeric form, its racemic form, its enantiomeric form, its diastereomeric form or them Or a pharmaceutically acceptable acid addition salt thereof, and the compound and at least one other cytostatic property different from the formula (1) or (1A) A pharmaceutical comprising an active substance or cytotoxic active substance.